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ABSTRACT
The aim of this study at the Brooklyn Chest Hospital (BCH) was to assess the
change in the oral carriage of Candida species in twenty-nine patients co-infected
with the Human Immunodeficiency Virus (HIV) and Tuberculosis (TB), before and
after anti-fungal treatment.
Each patient accepted onto the study underwent a comprehensive oral and peri-oral
examination where the presence, site and clinical features of all oral and peri-oral
lesions were recorded. The purpose of the examination was to provide a clinical
diagnosis of oral candidasis.
Each patient was also asked to provide a sample of oral fluid for laboratory analysis.
This was collected using an oral rinse. The results of a variety of laboratory
investigations were used to identify the species of Candida obtained from the oral
rinse. Both the oral and peri-oral examination and the oral rinse procedure were
repeated after one month and at three months.
A sample from each oral rinse was inoculated on CHROMagar Candida chromogenic
medium (CHROMagar Candida, France, Paris).
CHROMagar is used for the isolation and presumptive identification of Candida sp.
from other yeasts on the basis of strongly contrasted colony colours, which are
produced by the reactions of species-specific enzymes with a proprietary
chromogenic substrate.
After forty-eight hours the CHROMagar plate was examined for growth, when a
record of colony morphology and colour was made. A single sample from each
different colour-coded colony was taken and streaked onto a Sabouraud plate
(Oxoid, Basingstake, England) and then incubated for forty eight hours at thirty-seven
degrees centigrade.
A variety of laboratory investigations were subsequently carried out on a single
colony taken from the Sabouraud agar plate (Oxoid). The results of these tests were
used to identify the individual species of Candida isolated from each oral rinse.
Oral candidasis was the most prevalent oral lesion observed on admission and at
three months.
Six different species of Candida were identified during this study, namely Candida
albicans, Candida dubliniensis, Candida krusei, Candida glabrata, Candida
parapsilosis, and Candida tropicalis. C.albicans was the most commonly identified
species in study population. Candida dubliniensis was isolated and identified for the
first time in a South African HIV population.
Each specimen of Candida sp. identified by laboratory analysis was tested for
sensitivity to Nystatin, Amphotericin B and Fluconazole anti-fungal agents. An
additional sensitivity test was performed using Ajoene and Allicin (extracts of garlic)
to assess the comparative antifungal properties of these compounds.
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OPSOMMING
Die doelwit van hierdie studie by die Brooklyn Borshospitaal (BCH) was om die
verandering in orale draerstatus van die Kandida spesies in nege-en-twintig HIVfTB
koïnfekteerde pasiënte vas te stel, voor- en na antifungale behandeling.
Elke pasiënt in die studie het 'n volledige intra- en ekstra-orale ondersoek
ondergaan. Die teenwoordigheid, area en kliniese voorkoms van alle letsels is
noteer.
Die doel van die ondersoek was om 'n kliniese diagnose van orale kandidiase te
verkry.
'n Monster orale vloeistof is geneem van elke pasiënt vir laboratorium analise. Die
monster is in die vorm van 'n mondspoel geneem. Verskeie toetse is gedoen om die
verskillende Kandida spesies in elke monster te identifiseer.
Die orale- en ekstra-orale ondersoek sowel as die mondspoelmonster is na 1 en 3
maande herhaal. Elke mondspoelmonster is op CHROMagar Kandida chromogene
medium (CHROMagar Candida, France) inokuleer.
CHROMagar word gebruik vir die vermoedelike identifikasie en isolasie van Kandida
spesies teenoor ander swamme. Dit word gedoen op die basis van kontrasterende
koloniekleure, wat teweeggebring word deur spesie-spesifieke ensiemreaksies op 'n
chromogene substraat.
Die CHROMagar plate is na 48 uur ondersoek vir groei en die kolonie-morfologie en -
kleur is noteer.
'n Enkel monster. is geneem van elke verskillende kolonie (geskei op kleur) en is
uitgestreep op 'n Saboraud plaat (Oxoid, Basingstoke, England). Dit is dan vir 48 uur
inkubeer teen 37°C.
Verskeie laboratorium ondersoeke is daarna uitgevoer op 'n enkel kolonie geneem
vanaf die Saboraud agar plaat (oxoid). Die resultate van die ondersoeke is gebruik
om individuele spesies van Kandida te identifiseer.
Orale Kandidiase was die mees algemene orale letsel geïdentifiseer by toelating en 3
maande ondersoeke. Ses verskillende spesies Kandida is identifiseer tydens die
studie, naamlik: Kandida albicans, K.dubliniensis, K.Krusei, K.glabrata,
K.parapsilosis en K.tropicalis. K.albicans was die mees algemeen identifiseerde
spesie in die studiepopulasie.
K.dubliniensis is vir die eerste keer in Suid-Afrika in 'n HIV<+lpopulasie isoleer en
geïdentifiseer. Elke monster van identifiseerde Kandida spesies is getoets vir
sensitiwiteit teenoor Nistatien, Amfotensien B en Flukonasool. Addisioneel is ook
getoets vir sensitiwiteit teenoor Ajoene en Allicin (knoffelekstrakte).
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Chapter 1
INTRODUCTION
The earliest descriptions of human candidosis appears to be that of 'oral
thrush', as noted in the writings of Hippocrates (600 BC), Galen (AD130) and
later others such as Samuel Pepys (1665).
In 1839 Langenbeck made the connection between oral thrush and a yeast.
Further work by Gruby (1842) defined the clinical picture of thrush and its
aetiological agent, assigning the organism to the genus Sporotrichum. Debate
continued with Robin (1853) reassigning it to the genus Oidium, where it was
first given the name Oidium albicans. In the early 1900's Castellani and
Chambers suggested that other yeasts might be aetiological agents in the
disease process, and reassigned it to the genus Monilia. Eventually in 1923
Christine Berkhout gave the name 'candida' to this group so differentiating the
'medical' monilia infections from the plant and leaf rotting moulds (as reviewed
by Odds)(1).
Candidosis* has gained prominence in the later half of this century,
particularly with emergence of the HIV/AIDS epidemic in the 1980's (2,3,4,5).
A greater understanding of Canedosis and its causative organisms, combined
with more sensitivity diagnostic investigations (for example computed
tomography, polymerase chain reaction and immmunoprecipitation) have lead
to a rise in the incidence of patients diagnosed with the disease. The
prevalence of oral candidosis in patients with the HIV infection ranges from
43-93% (6,7).
HIV patients are also vulnerable to opportunistic infections such as
tuberculosis, where both the immuno-suppression and drug therapy further
increase the risk of candidal infections. Advances in drug therapy have been
responsible for the remarkable success in oncology and organ transplantation
therapies (8). Management of these complex drug regimes frequently requires
patient hospitalisation. Researchers have reported a dramatic increase in
susceptibility to oral and systemic candidosis in the nosocomial environment
(6,9,10,11,12).
Studies found that AIDS patients who fail to respond to standard antifungal
therapy for oro-pharyngeal cancldosis show a median survival of 184 days
after the onset of fluconazole resistant pseudo-membranous oral candidosis,
and only 83 days after the onset of clinical resistance to Amphotericin B.
Although oral candidosis is not a direct cause of death, evidence suggests
that failure of antifungal treatment is most probably a co-morbidity factor in the
rapid demise of AIDS patients.
*Oral candidosis is the collective name given to a group of clinical disorders caused by the
yeast Candida. The term 'Candidosis' is adopted in this text rather than candidiasis, as the
suffix 'osis' is consistent with the ending used in the vast majority of fungal infections, for
example histoplasmosis, aspergillosis.
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Candida species are generally regarded to be normal commensal micro-
organisms of the oral cavity (13). Candida species can also be opportunistic
pathogens (9,14,15,16,17). With the advent of HIV infection there has been
renewed interest in the pathogenesis and sequelae of fungal infections,
particularly in South Africa where oral and/or pharyngeal candidasis is present
in a high percentage of HIV/AIDS patients (18). Although C.albicans has been
cited as the most common pathogen in oral candidasis, there is growing
evidence that non - C.albicans species, including C.krusei and C.glabrata,
playa significant role in oral disease (19,20,21-25). In 1995 a new species,
Candida dubliniensis, was identified (26,27,28). This species shares many
phenotypical characteristics with C.albicans, which may account for its earlier
misidentification (29,30,31,32). C.dubliniensis appears to be a clinically
important species in HIV/AIDS patients (33,34,35,36). It has the potential to
initiate oral disease, perhaps acting as an independent or symbiotic pathogen
(37,38,39). C.dubliniensis is susceptible to existing anti fungal drugs but
possesses the ability to develop stable resistance to fluconazole following
direct exposure to the drug in vitro (40,41,42).
While C. dubliniensis has been isolated in Argentina, Australia, Brazil, Europe,
Israel, North America and Switzerland, it has not been identified in Africa
(29,43,44).
An extensive amount of research has been conducted into the incidence and
prevalence of HIV infection / AIDS associated oral lesions (45). A review of
the literature indicates that there has been no documentation or investigation
of the oral cavity of HIV/AIDS and TB co-infected patients. The aetiology of
any oral lesion in this patients gr· IUp is likely to be extremely complex.
12
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Chapter 2
Literature review
2.1 The genus Candida
The Candida species are classified as Fungi Imperfecti (Deuteromycetes) as
the perfect or sexual phase of their reproduction has not been discovered
(46). Fungi are eukaryotic, hete otrophic organisms that possess a rigid cell
wall but lack chlorophyll. There are two basic morphological forms: yeasts and
moulds. Yeasts are unicellular structures that reproduce by budding and less
commonly internal subdivision of their cytoplasm. Moulds are multinucleate
and grow in long filamentous patterns. These filaments are called hyphae and
are subdivided by cross walls known as septae. C.albicans and C.
dubliniensis also form a third morphological form called pseudohyphae. As
with the yeast form, the pseudohyphae appendage arises by budding, with a
characteristic stricture between mother and daughter cells. This appendage
continues to elongate, giving the appearance of a hyphal form. Nutritional
factors play the most important role in determining which of the three
morphologies of C. albicans and C. dubliniensis is generated.
C. albicans and C. dubliniensis also possess a second quality that enables
them to be distinguished from other Candida species. They are able under
certain conditions to produce chlamydospores. Chlamydospores are spherical
structures that form at the tip of the hyphae and appear when the organism
grows in a nutrient poor environment (47).
Candida sp. have been reported in almost every tissue of the human body,
living in the moist, warm areas i.e. for oral cavity, vagina, gastrointestinal tract
and skin folds. Studies that have investigated the prevalence of Candida sp. in
the general population have produced variable results due to different
sampling techniques used and study populations investigated. (1,48,49).
Healthy individuals appear to have a lower carriage of Candida sp. than those-
with predisposing conditions (18,50). Approximately 17 to 58% of hospitalised
patients carry Candida sp. on their hands (51).
Although more than 150 species of Candida sp. have been identified only a
relatively small number are human pathogens. Candidoses can be divided
into superficial and systemic infections. Systemic candidoses are relatively
uncommon, but have serious consequences (52). Superficial candidoses can
affect the mucosa of the oral, vaginal and aural cavities, the genitalia, skin and
nails.
C.albicans is the most prevalent yeast and commonly identified fungal
pathogen in humans. Other species isolated from the human body included
C.dubliniensis, C.glabrata, C.krusei, C.guillermondii, C.tropicalis,
C.parapsilosis and C.kefyr (previously Candida pseudotropicalis
(17,19,20,26,53).
13
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2.1.1 Candida dubliniensis
A new species of Candida, C.dubliniensis was identified in 1995 (26). The
earliest isolate now known to have been C. dubliniensis was recovered from a
post mortem lung specimen from a patient who died in the UK in 1957. This
strain was misidentified as a strain of Candida stellatoidea. In the late 80's
and early 90's atypical Candida isolates were identified in HIVand AIDS
patients in Australia, Ireland and the United Kingdom. In 1995 it was decided
that these isolates represented a new species of Candida. This new species
(dubliniensis) was named after Dublin the capital of the Republic of Ireland
where it was first proposed (26). Since then isolates have been reported in
Argentina, Australia, Belgium, Canada, France, Finland, Germany, Greece,
Ireland, Spain, Switzerland, Brazil, Israel the UK and the United States of
America (27,28,29,33,43,44).
C.dubliniensis is a chlamydospore and germ tube positive yeast and was
initially associated with HIV pcsitlve and AIDS patients (18,30,33,34,35).
C.dubiniensis has also been recovered from HIV negative individuals with
clinical signs of oral candidosis (54). C.dubliniensis is frequently isolated with
other Candida species, the most common being C.albicans.
Research results indicate that C. dubliniensis is a minor component of the
normal oral microflora of humans. Studies from the USA have isolated
C.dubliniensis in systemic candidosis (55).
Studies have demonstrated that in vivo populations of C.albicans can include
a large number of subtypes, which differ in their relative susceptibility to
antifungal agents. Exposure to fluconazole in vitro can give rise to stable
resistance to this anti-fungal agent but such resistance has not been
convincingly demonstrated in vivo (56). The development of such resistance
may depend on the dosage of drug administered, the duration of therapy, or
on the immune status of the patient. C.dubliniensis, unlike C.albicans
possesses the ability to rapidly develop stable resistance to fluconazole
following direct exposure to the .-;rugin vitro. An Irish study has reported that
C. dubliniensis encodes multi-drug transporters which facilitate efflux of
fluconazole from the cell via specific multi-drug transporters (MDR1). However
strains of C. dubliniensis that demonstrated reduced susceptibility to.
fluconazole remained susceptible to Amphotericin Band 5FC (40,41).
2.1.2 Candida glabrata
Until the early 1980's C.albicans was regarded as the only human pathogen of
this genus. With the advent of the HIV infection and widespread use of
immunosuppressive therapy, there has been an increase in the number of
infections caused by species other than C.albicans. These non-Candida
albicans species are reported to account for the dramatic rise in nosocomial
transmission and candidal infections in immuno-suppressed patients (57-62).
Several species that were regarded as non-pathogenic are now recognised as
human pathogens (19,34,57,63-5).
14
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The generally non-pathogenic nature of C.glabrata in animals would suggest it
has few virulence factors. The high paediatric mortality rate and the rapidity
with which candidasis caused by a C.glabrata is communicated within
hospitals, indicates that it is an important human pathogen (19).
2.1.3 Distribution of yeasts in the mouth.
Many studies have attempted to report on the prevalence of Candida sp. in
humans. Variations in the parameters used by the different investigators such
as patients selection, sampling techniques and the technique of the operator,
have not permitted proper comparison and interpretation of the results
(1,48,49).
Yeasts are acquired in several ways; person to person contact, for example
from a mother to baby at birth, from the environment to the individual, or from
one body site to another (13,14,51,66). Colonisation of the oral cavity by
Candida sp. is low during the first few days of life, then increases over the
next eighteen months to a peak at two years after birth (13). Thereafter the
carriage rate falls during childhood but appears to rise again later in life.
The oral carriage rate for Cer.dkie sp. in healthy individuals varies from
between 2-71 %, where again sampling methodology and identification
techniques play a significant role in quantification (1,48,49). Individuals
sampled in hospital while attending for treatment or diagnosis of disease
tended to show consistently higher values of Candida sp. carriage compared
to their healthy counterparts (18,50,67).
There is broad agreement as to the distribution of Candida sp. in the healthy
oral cavity. C.albicans is the single most commonly isolated species both in
disease and in health, with C. glabrata and C.tropicalis next most frequently
isolated group, and C.parapsilosis, C.guillermondii, C.krusei and C.kefyr
infrequently isolated.
Studies using the imprint sampling method have yielded results of 10-20
colonies per cm2. The number of Candida cells per millilitre of oral fluid in
normal healthy carriers ranges from 200 - 600 CFU I ml (49).
In dentate individuals yeasts arc most commonly isolated on the dorsum of_
the tongue. The buccal mucosa, floor of the mouth and angles of the mouth
are less common sites for yeasts.
Very little work has been done on Candida sp. distribution in patients infected
with the HIV, or with other immune-compromised states. A study found that
gingival biopsies from HIV sera-positive patients with gingivitis demonstrated
the presence of pseudohyphae of Candida sp. in the parakeratinised oral
epithelium (68). The sera-negative group showed no evidence of Candida sp.
invasion.
Candida dubliniensis has been implicated in the aetiology of linear gingival
erythema, which is found in patients with the HIV infection (37).
Although the presence of Candida sp. in dental plaque is contentious, one
study suggested that C.albicans can invade dental hard tissue and thus act as
a potential reservoir for disseminated candidal infection (69).
15
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2.1.4 Morphogenesis of Candida sp.
Candida sp. grow aerobically in a temperature range of 20 to 47°C with an
optimum growth at 37°C. The pH range for Candida sp. growth is between 2-
8. Both C.albicans and C.dubliniensis respond to changes in the
environmental pH with a change in cell shape and differential gene expression
(70). .
Candida sp. can exist as yeasts where they replicate by budding or as a
hyphal form (46). It was previously thought that the yeast form was primarily
seen in the commensal state whereas the presence of hyphal and pseudo-
hyphal forms indicated an infectious state (71). C.glabrata only exists in yeast
form and is now known to act as a human pathogen (19).
C.albicans exhibits several different morphological forms under different
environmental conditions, including budding yeast cells (blastospores),
pseudohyphae, true hyphae and chlamydospores. The yeast form is favoured
at temperatures below 33°C, where as at elevated temperatures and near
neutral pH mycelial growth is favoured. One study found that commensal and
transient oral bacterial populations might selectively influence the differential
expression of germ-tube-forming ability of C.albicans isolates (72).
Chlamydospores are special structures at the tips of hyphae and appear
under poor nutrient conditions (73). Pseudohyphae are encountered in vivo
and in vitro. The morphogenic f,;rm of Candida sp. appears to be principally
determined by alterations in cell metabolism.
Candida species are differentiated by colony morphology, colour on
differential media, as well as carbohydrate assimilation and fermentation
patterns of the species (46,47,74,75). Newer technology has allowed for more
accurate identification (76,77,78).
2.1.5 Candida cell wall and antigenic structure
The structure and composition of the cell wall is an important feature, as it is
involved in adhesion and colonisation of epithelium and mucosa (79,80). It is
composed of beta-glucans, which are thought to provide its structural integrity,
mannoproteins and a small quantity of chitin (81-4). Similar proportions of
these polymers are found in yeast and mycelial states. Transmission electron-
microscopy has demonstrated that the wall is composed of five distinct layers
with some species having an outer fibrillar layer. The main antigenic
component of the cell wall is the mannoprotein fraction (79,85).
C.albicans possess a 'fuzzy' coat and the fibrillar layer is contained within this
coat. This fuzzy coat is believed to be important in the overall virulence of the
organism by affecting adherence and phagocytosis (86,87). Another important
feature of the cell surface of C.albicans is the presence of receptors for the
complement fragment C3b. C.albicans binds Cb3 non-covalently, impairing
the phagocytic uptake of the yeast by human polymorphonuclear leucocytes
(88).
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Antibodies against certain cell surface antigens of C.albicans help the host
resist disseminated candidiasis (89). The cell wall also offers targets for anti
fungal agents; the beta-glucans and chitin of the cell wall are not present in
the human host and therefore could offer potential targets for future
generations of antifungal medication.
2.2. Virulence factors of Candida sp.
An increasing number of viruteri .e factors are being identified in Candida sp.
infections of the oral cavity. .
2.2.1 Germ tube formation and contact sensing
Germ tubes, which mark the onset of hyphal growth of C.albicans, are
suspected of being involved in the pathogenesis of candidosis (90,91).
Besides C.albicans and C.dubliniensis germ tubes have also been observed
in strains of C.tropicalis. In the case of minor immunosuppression the
expression of virulence factors for adherence and germ tube formation plays
an important role in the pathogenesis of candidosis (92).
Deeper penetration of keratinised epithelia is assisted by hyphaI formation
and by the presence of hydrolytic enzymes, which are located in the tips of the
hyphae (93). C.albicans may use contact sensing (thigmotropism) as a
guiding mechanism (94).
A hyphae-specific surface protei" Hwp1 isolated from C.albicans, which has
similarities with the mammalian small proline rich proteins, has been shown to
serve as a substrate for mammalian transglutaminases. Researchers found
that C.albicans strains, which lack the protein Hwp1, are unable to form stable
attachments to human buccal epithelial cells. In mice, these strains have a
reduced capacity to cause systemic candidosis (95).
2.2.2 Adhesion of Candida sp. to mucosa
There is good evidence that adherence of the fungus to the surface of the oral
mucosa is a critical prerequisite for permanent colonisation or infection of a
site (96-9). This is certainly true for the oral cavity, where the mechanical
washing by oral fluid and the action of the oral musculature are very powerful
defence mechanisms. Adherence values do appear to vary between
individuals. There is evidence of a daily variation in the attachment affinity of
the same yeast cell to human buccal epithelial cells. Fluctuations in the level
of certain hormones also appear to affect the adherence of C.albicans to
human buccal epithelial cells (1CJ).
Research investigating HIV positive individuals appears to indicate that there
is an association between the HIV infection and the selection of C.albicans
strains, which have an increased ability to adhere to oral mucosa (101-3). A
study found that the use of anti-bacterial medication and zidovudine were
associated with increased adhesion of Candida sp. to buccal epithelial cells
(101). These findings may explain the high levels of oral Candida carriage in
HIV I TB co-infected patients.
Studies on paediatric burns patients reported no correlation between
C.albicans adhesiveness and the site of isolation (autographs, blood, faeces,
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throat swabs, tracheal aspirates, wounds, intravenous catheters) although
isolates from catheters were generally less adhesive to epithelial cells (104).
The same study using a model of a systemic candidal infection in mice found
no correlation between the virulence of isolates and the biotype, serotype or
the site of isolation (104).
C.krusei is emerging as an important pathogen of oral candidosis in
immunocompromised patients. In a comparative study C.krusei showed
significantly higher hydrophobicity than C.albicans isolates. The researchers
noted a correlation between the surface hydrophobicity of C.krusei and its
adhesion to epithelial cell surfaces (105).
Glycosides containing L-fucose or N-acetyl-D-glucosamine can act as
epithelial receptors for C.albicars (106). In insulin-using diabetic patients the
adhesion of C.albicans was influenced by the availability of sugars in the
growth medium, as well as the strain of C.albicans present. In these patients
palatal epithelial cells appeared to retain significantly more C.albicans in vivo
(107).
2.2.3 Adhesins
Candida sp. adhesion molecules appear to be of three general types. In one
type the protein moiety of a surface glycoprotein binds to arginine-glycine-
asparate sequences common to fibronectin, vitronectin, collagens, laminin
and other extracellular glycoproteins (80). In the second type the protein
moiety of a surface glycoprotein binds in a lectin-like manner to a sugar
portion of host membrane glycoproteins. In the third and least well
understood, the polysaccharide moiety of a Candida sp. surface mannoprotein
binds to unknown host receptors (84).
Several potent adhesins are associated with the fibrillar coat and fimbriae of
fungi (86,108). Mannoprotein appears as a component of the fibrillar
outermost layer of the fungal cell wall (99,109). CaMNT1 is a gene involved in
the synthesis of mannoproteins. This gene encodes for an enzyme required
for the correct mannosylation of proteins that appear to be critical for adhesion
of C.albicans (85).
Studies that have examined the nikkomycins (chitin synthetase inhibitors),
demonstrated that C.albicans adhesion to buccal epithelial cells shows
reduced adhesion and changed fungal morphology in the presence of these
agents. This points to involvement of chitin in the adhesion of C.albicans to
buccal epithelial cells (110).
In order to approach and to bind to mucosal epithelial cells Candida sp. must
traverse the overlying mucus layer. C.albicans, C.dubliniensis and C.tropicalis
all adhere well to mucin. C.parapsilosis and C. lusitaniae are moderately
adherent, while C.glabrata and C.krusei are weakly adherent to mucin.
Adherence of C.albicans to buccal epithelial cells is quantitatively inhibited by
graded concentrations of mucir (111). A study found that C.albicans may
adhere to and enzymatically degrade mucins through the action of secretory
aspartyl proteinase. These properties may act to modulate Candida sp.
populations in the oral cavity and gastrointestinal tract (111).
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2.2.4 Propensity to switch phenotype
When grown in vitro C.albicans can exhibit a switch from smooth white
colonies to other variant forms such as the star-shaped, opaque or
rough/wrinkled colony forms. This ability is called phenotypical switching (112-
4). Under certain conditions both C.albicans and C.dubliniensis are able to
switch colony phenotype (115). A variety of environmental conditions including
a change in pH and low dose UV light will lead to differential gene expression
and expression of variant colony form.
C.tropicalis and C.glabrata are also known to possess this type of switching
potential.
A correlation exists between the phenotypic characteristics of the fungal strain
and the adhesion potential of the blastospore to buccal epithelial cells.
Candida strains that exhibit rough or coarse fringes demonstrated a greater
potential for adhesion (86,116).
Phenotypical switching may enhance the pathogenic potential of C. albicans
increasing its capacity to invade and proliferate in the different body
environments. C.albicans strains isolated from deep-seated infections appear
to display a higher frequency of phenotypical switching than strains isolated
from more superficial infections (117).
2.2.5 Surface hydrophobicity
Surface hydrophobicity is a non-specific factor that can govern mutual
adhesion of cell types via van der Waal forces. The exact role that
hydrophobicity plays in Candida sp. virulence is poorly understood, but there
is a strong correlation between cell surface hydrophobicity and adhesion
(118). Candida sp. cells with hydrophobic surfaces are more adherent that
than those with hydrophilic surface areas (119). Hydrophobic interactions are
involved in the adherence of C.albicans and C. parapsilosis to buccal
epithelial cells and acrylic surfaces (120). C.dubliniensis appears to lack the
cell surface hydrophobicity entities, which could account for its limited ability to
cause disseminated infections (121).
The degree of hydrophobicity of the different strains of C.albicans is
determined by a variety of factors including temperature, the phase of growth
and changes in the surface exposure to cell wall proteins (122). Anti-myeetles
are believed to reduce cell surface hydrophobicity.
2.2.6 Lytic enzymes
The majority of candidal proteinases are glycoproteins of approximately 45
kDa molecular mass and are related to pepsin, rennin and cathepsin D.
Fungal proteinases degrade serum albumin into small fragments and this
indicates low substrate specificity. Very few proteins were found to resist
degradation by candidal proteinases at acidic pH. All the noted enzymic
effects of candidal proteinases were found to require a low pH. Physiological
pH at 37°C inhibits the activity of candida proteinases and causes alkaline
denaturation. Candida sp. isolates that are antifungal resistant produce more
proteinases than antifungal sensitive isolates (123).
Secreted aspartic proteinases (SAPs) are important virulence factors involved
in adherence mechanism of some Candida sp. to the oral mucosa
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(124,125,126). Aspartic proteinase is either secreted by C.albicans or present
in the cell wall and is able to hydrolyse secretory IgA, complement factor 3,
albumin and keratin. Secreted aspartic proteinases facilitate tissue penetration
and may possess auxiliary roles as adhesins acting singly or synergistically to
enhance the adhesiveness of C.albicans (125). Invasive isolates of C.albicans
secrete higher concentrations of proteinases and adhere more readily to
mucosal surfaces (127,128).
Pathogenic Candida sp. also secrete membrane damaging phospholipase A,
Band C (129). Studies have found that phospholipase-producing strains
adhere most strongly to epithelial cells. The production of phospholipases by
Candida sp. correlates with pathogenicity and is predicative of mortality in
animals (130). These phospholipases are produced by virulent strains but not
commensal organisms.
A study of the pathogenic traits of C.parapsilosis isolates found a relationship
between the phosphatase activity, as measured with p-nitrophenol phosphate,
and the adhesion of the yeasts to the buccal epithelial cells. The research
implied that both alkaline and acid phosphatases of Candida sp. might playa
crucial role in potentiating the virulence of Candida sp. (131).
2.2.7 Mitogen Activated Protein Kinases (MAPkinases)
MAP kinases in eukaryotic cells are important for the transduction of a variety
of extracellular signals that regulate cell growth and differentiation. MAP
kinases homologous to yeast Fus3/Kss1 MAP kinases have been identified in
several fungal pathogens and found to be important in fungal pathogenesis
i.e. invasive hyphal growth, as well as differentiation and survival (132).
2.3 Host factors and oral candidosis
2.3.1 Predisposing factors for Candida infection
The specific oral profile of Candida sp. in a healthy individual may be modified
by a variety of host factors including nutritional state, presence of disease, use
of medication, and the composition of the oral environment (133). Malnutrition,
a carbohydrate rich diet, vitamin and iron deficiency can all contribute to the
development of candidosis (1,134). The use of antibiotics is an important
factor in increasing the risk of developing Candida sp. infection (135,136).
Broad-spectrum rather than narrow spectrum antibiotic therapy leads to
Candida sp. overgrowth and is a predisposing factor for deep candidosis (137-
139). The weight of available data implies that although antibiotics can
influence the oral carriage of Candida sp. the extent of affection would appear
to be dependant on additional local and host factors, together with the strain
of Candida sp. in question (140-145). The basic mechanism by which
antibiotics enhance candidal growth is by reducing the commensal bacterial
population.
Local host factors of the oral cavity are crucial determinants of Candida sp.
survival, and for the development of the disease state. These factors include
the integrity of the oral mucosa, the expression of micro-structural protein
receptors of the oral epithelial cells, anti-candidal factors, the glucose
concentration of oral fluid, other competitive oral microflora, the pH and the
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temperature of the oral cavity. Trauma and existing infections may contribute
and precipitate the development of candidosis. For example super-infection
with Candida sp., which occurs in severe burn injuries and in superficial
infections caused by Staphylococcus aureus, or the Herpes virus (146-48).
Pregnancy, oral contraception, some spermicidal preparations (Nonoxynol-9),
tight fitting stockings, and hormonal changes are all reported as being risk
factors for the development of vaginal candidosis, a common affliction of
women (109,149-153).
A fully developed and intact immune system is critical for protection against
Candida infection. Neonates who have an immature immune system are
prone to developing Candida sp. infections (154-157). The importance of the
immune system with regard to Candida sp. is illustrated in patients with
defective immune systems, such as those with certain endocrine disorders
and genetic immune defects, who suffer from chronic mucocutaneous
candidosis (1).
Candidosis has been described as the "disease of the diseased", as it
frequently occurs in patients with debilitating illness such as diabetes mellitus,
AIDS and haematological malignancies (158-160).
2.4 Host response
The initial host defences are the non-specific barriers including intact skin and
mucosal epithelium, as well as indigenous bacterial flora that compete for
binding sites. The body is protected from microbial invasion by a variety of
factors, two of the most important anti-candidal defences are epithelial
proliferation and the cellular immune response. Observations and histological
examination of the epidermal proliferation encountered in chronic
mucocutaneous candidosis shows massive hyperkeratosis at a rate equal to
or greater than the rate of fungal penetration of the epidermis (161). There is
little evidence to support that this proliferation occurs during Candida sp.
invasion of the vagina or oral mucosa (162).
Evidence indicates that cell-mediated immunity is a key factor in the primary
host defence of superficial candidosis, whereas neutrophils and possibly
macrophages are important in deep candidosis (163-4). The evidence for the
importance of cellular immunity in defence against mucosal and cutaneous
Candida sp. infections comes from observations of patients with definable T-
cell defects (165). Patients with AIDS often suffer from oral candidosis but
less commonly have deep Candida sp. infections, while patients with
haematological and other malignancies who become neutropenic during
chemotherapy are at more risk for deep Candida sp. infections (166-9).
Langerhans cells may playa role in the generation of T-lymphocyte responses
to cutaneous Candida sp. infection (170).
Various aspects of cell-mediated immunity involved in oral candidosis and
chronic mucocutaneous candidosis have been examined. Defects in cell-
mediated immunity to Candida sp. antigens (as manifest by negative delayed
hypersensitivity reactions) and abnormal in vitro assays of lymphocyte
function (showing impaired cytotoxic or migration inhibition factor responses)
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support the important role cell-mediated immunity plays in these types of
candidal infection.
The major cell surface antigen of Candida sp. is mannin (171). C.albicans is a
constituent of the normal gastrointestinal flora and the majority of humans will
show evidence of low levels of antibodies to Candida sp. mannin. In infected
patients, elevated levels of Candida-specific antibodies have been found
representing the IgG, IgM ani IgA immunoglobulin classes. Secretory
immunoglobulin A (sigA) levels in oral fluid are elevated in Candida sp.
stomatitis. It is produced in response to Candida sp. antigen and protects
against mucosal colonisation (172-3). The role of Candida-specific antibodies
in host defence against disseminated candidosis is unclear, as patients who
develop disseminated candidosis frequently have Candida-specific antibodies
in their serum (174).
Although antibodies titres to various Candida sp. antigens are raised during
infection, it has been demonstrated that the humoral response does not
appear to play an important role in host defence against Candida sp.
infection.
2.4.1 Pathogenesis of oral candidosis
A range of different host and fungal factors play a critical role in the
pathogenesis of Candida sp. infection. Initial colonization will be determined
by the surface adhesive comp..ments of the fungus as well as local host
defences and competing oral microflora. Researchers suggest that
unconventional immune cells have some role in host defence (170). Epithelial
cells inhibit the growth of C.albicans and endothelial cells are able to
phagocytose C.albicans. C.glabrata does not appear to induce endothelial cell
phagocytosis, which suggests that endothelial cell phagocytosis may be
species-specific or restricted to C.albicans alone. Keratinocytes are capable of
phagocytosing C.albicans cells (175). Other cell lines, monocytes and
eosinophils, are also capable of anti-candidal activity but playa far smaller
role. Human natural killer cells are non-phagocytic large granular
lymphocytes, which are cytotoxic to certain tumour cell lines and to virally
infected cells. Although large granular lymphocytes themselves do not have
any antifungal activity, studies have reported when stimulated by C.albicans
these cells secrete a potent activator of polymorphonuclear leucocytes.
Research suggests there is a complex relationship between C.albicans and
natural killer cells.
The major cellular defence mechanism against Candida sp. consists of
phagocytosis by polymorphonuclear leucocytes and macrophages (176).
Polymorphonuclear leucocytes (PMNL) are the cells of foremost importance in
this initial response (177,178). The phagocytosis and intracellular killing of
yeast cells is enhanced by the presence of opsonins, with opsonised cells
ingested by phagocytes at a faster rate than non-opsonised cells (179-81).
Neutrophilic granulocytes themselves may allow yeast phase C.albicans to
evade intracellular killing. The internal milieu of the phagosomes is acidic and
therefore competition between acid fungal hydrolases and acid hydrolases of
the phagosome may determine the outcome of the phagocytosis.
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There are two mechanisms by which PMNL can destroy Candida sp. One is
mediated by the myeloperoxidase-hydrogenperoxidehalide system and the
second is still as yet unidentified (182-3). Researchers demonstrated the
myeloperoxidase-hydrogeperoxi('e-halide system in PMNL could be initiated
by Candida sp. mannan (184). PMNL's exert a fungistatic effect on yeast cells
(185). This effect is seen when PMNL's lyse in areas of dense infiltrates of
yeast cells. A fungistatic cytoplasmic protein is released during the lytic
process, which may possible control the infection and prevents further spread.
PMNL's can be considered to be equally efficient against both C.albicans and
C.dubliniensis (176).
Macrophages adhere to the mannose residues of Candida sp. via their
mannose receptor (186). This process is calcium dependant. Phagocytosis by
the macrophage stimulates the production of H 202 and oxygen radicals and
the killing of ingested Candida organisms (187).
As well as phagocytosing blastospores macrophages are also capable of
damaging non-phagocytosable pseudohyphae and hyphae (188). Although
the method of destruction is not fully understood, it appears that this
mechanism may playa role in the destruction of pseudo- hyphae and hyphae
that are too large to be phaqocytosed. This hypothesis is supported by the
observation that macrophages are able to differentiate between yeasts and
hyphae and respond to each selectively (189). In addition macrophages may
further be stimulated by myeloperoxidase released by PMNL's, to produce
more reduced oxygen derivatives and induce cytokine production (190).
T-cell enhancement is important for the body to mount an effective immune
response (191-2). Unstimulated phagocytes (PMNL's and macrophages)
provide a relatively ineffective immune response, eliminating approximately
20-30% of ingested Candida (193). The immune response may be enhanced
via two mechanisms; a. T-cell-independent route, or b. T-cell dependant
route.
a. T cell independent route:
Macrophages can be activated by myeloperoxidase, which is released into the
environment by PMNL's (194-5). Anti-Candida macrophage activation has
been observed with Candida-m;.:nnan, avirulent C.albicans strains and other
microbes (196-99). Studies have found that activated macrophages produce
more reduced oxygen derivatives, induce cytokine production and destroy
higher numbers of Candida organisms (190).
b. T cell dependant route:
Candida sp. adherence induces mucosal cells to presentation of MHC II class
antigens (DO and DR)(200). These cells are phagocytosed by macrophages,
which present an antigen to T-lymphocytes and possibly Langerhans cells.
Activated T-cells release cytokines, interferon-gamma and tumour necrosis
factor-alpha (TNF-alpha). Interferon gamma activates macrophage production
of tumour necrosis factor alpha, which in turn activates PMNL's to enhanced
killing of Candida sp. (201). The concurrent release of cell-growth stimulatory
factor (C-GSF) also induces the production of more leucocytes in the bone
marrow (269).
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Research using murine models have demonstrated that colonisation by
C.albicans induces a T-helper-1 (Th1) or T-helper-2 (Th2) lymphocyte
response (203-06). Studies on mice have shown that Th-1 type response
characterized by cytokines interleukin-2, Interferon gamma and interleukin-12
is associated with protection against systemic infection whereas Th-2 type
responses characterized by cytokines interleukin-4, interleukin-5 and
interleukin-10 and antibody p .duction, IgA and IgE is associated with
susceptibility to systemic Candida sp. infections.
2.4.2 Inhibition of the immune system
Inhibition of parts of the immune defences of the host by C.albicans has been
observed by a number of researchers with regard to chronic mucocutaneous
candidosis.
A polysaccharide fraction of C.albicans has been shown to inhibit the
proliferation of human T-Iymphocytes and the production of interleukin-1 and
2.
2.4.3 Prostaglandins
Enhanced prostaglandin production during fungal infection could be an
important factor in promoting fungal colonization and chronic infection (207).
Host cells are one source of prostaqlandins, however another potential source
of prostaglandins is the fungal pathogen itself.
Most cells in vivo seem to produce prostaglandins, most commonly
prostaglandin E2 (PGE2) and prostaglandin F2alpha. Both these
prostaglandins play a part in inflammation by intensifying the effects of
chemical mediators of inflammation such as histamine. A study isolated a
PGE series lipid from C.albicans and Cryptococcus neoformans, which was
biologically active on both fungal and mammalian cells. The fungal PGE (x)
enhanced the yeast to hyphae transformation in C.albicans. In mammalian
cells fungal PGE (x) down regulated chemokine production, TNF alpha
production and splenocyte production while up-regulating interleukin-10
production.
Prostaglandins-like compounds are produced only by pathogenic fungi, which
are critical for the growth of the fungi and can modulate host immune
functions (207).
2.4.4 Interference with complement (C)
The protection mechanism of complement appears to be associated with
enhanced phagocytosis and killing of the fungus even in the presence of the
HIV infection (208-09). The presence of the HIV infection may promote fungal
virulence by inducing hyphae formation, but may also be active in reducing
virulence by augmenting phagocytosis (210-11).
2.5 Clinical presentation and classification of oral candidosis
Clinically the oral candidal lesion can present in a variety of forms. In 1966
Lehner proposed a concise classification for oral candidosis. However with the
advent of the HIV infection and the accompanying increase in research on
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Candida, various authors have suggested modifications to his work.
Holmstrup and Bessermann in 1983 suggested a c1inico-pathological
classification, which would for irstance more accurately distinguish between
erythematous and atrophic forms of oral candidosis.
Candida sp. can produce a wide variety of human infections but can broadly
be classified into superficial and deep infections. Superficial candidosis
involves the skin, nails and mucous membranes of the oral cavity and the
vagina. Deep candidosis include candidaemia, localised infections of various
deep tissues and disseminated candidosis in immuno-suppressed patients.
This classification is significant as the host defence involved in the two types
of infection may be different.
2.5.1 Classification of oral candidoses
Classification taken from Handbook of Oral Disease by C.Scully (1999)
Acute/chronic Current nome iclature
Subgroup
Acute Acute pseudomembranous
Chronic Chronic pseudomembranous
Acute Acute erythematous
Chronic Chronic atrophic (denture-induced sore mouth)
Chronic Chronic mucocutaneous
Chronic Chronic hyperplastic
Acute/chronic Angular chelitis
In 1962 Newton proposed that chronic atrophic lesions of the palate could be
further categorised:
Newton's type 1: pin-point lesions- Localised simple inflammation
Newton's type 2: diffuse erythema - Generalised simple
inflammation
Newton's type 3: granular - Papillary hyperplasia
In 1985 Ohman suggested expanding on the subdivisions of angular chelitis
to define the degree of clinical involvement including the depth and number of
folds (rhagades)
type 1
type 2
single fold or rhagades limited to the corner of the mouth.
the lesion is more extensive in depth and length than type 1
lesions
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type 3 several fissures / rhagades radiating from the angle of the mouth
into the adjacent skin with the skin redness limited to the vicinity
of the rhagades
type 4 no rhagades evident but extensive erythematous area of the
skin adjacent the vermillion border
The pseudomembranous form of candidosis is prevalent in patients who are
infected with HIV or diagnosed with AIDS. This form of candidosis, if left
untreated may persist for several months, so can be classified as a chronic
form of the disease. The erythematous form of oral candidasis may be related
to sloughing of pseudomembranous lesions or may be a separate entity. It
appears that the erythematous form may affect any part of the oral cavity.
Linear gingival erythema is a clinical description for a prominent well-
demarcated, fiery red band that appears to follow the limits of the
physiological sulcus common in patients infected with HIV or in patients with
AIDS. Recent research has implicated Candida sp., in particular C.
dubliniensis, in the aetiology and pathogenesis of this condition.
Candida oesphagitis is a diagnostic characteristic for AIDS, presenting as
thick tan covered plaques, which can extend towards the gastro-oesphageal
junction.
Another characteristic feature of oral candidasis in AIDS patients is that
different forms of the disease can appear at different sites in the oral cavity at
the same time. These lesions can also be of a chronic nature often termed
chronic multi-focal oral candidasis.
2.6 Diagnosis and Laboratory identification techniques
Oral candidasis can be diagnosed from the patient history and clinical picture
alone. However a clinical diagnosis is best augmented with a laboratory tests
specific for fungal identification.
There are a variety of methods for isolating yeasts from oral samples:
• Smear - direct microscopy smears taken from lesional tissue (phase
contrast or PAS stain techniques).
• Swab - obtained by rubbing a sterile cotton-tipped swab over lesional
tissues. C.albicans can survive at least 24 hours on a moist swab
without loss of viability, however rapid transportation to the laboratory
decreases the risk of desiccation.
• Imprint culture technique - Sterile plastic foam pads are dipped in
Sabouraud's broth and then applied to the surface under investigation
for 60 seconds. This is a reliable and sensitive method of sampling.
• Impression culture technique - this technique involves taking maxillary
and mandibular alginate impressions, transportation to a laboratory, for
casting in 6% fortified agar with incorporated Sabouraud's dextrose
broth. The agar models are then incubated in a wide necked sterile
screw topped jar for 48-72 hours at 37° C and the colony forming units
of yeasts estimated.
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• Salivary culture technique - involves requesting the patients to
expectorate 2ml of mixed unstimulated saliva into a sterile universal
container, which is then vibrated for 30 seconds to achieve adequate
disaggregation. The number of Candida is estimated by counting the
resultant growth on Sabouraud's agar and expressed as colony forming
units/ml of saliva.
• Oral rinse technique - consists of requesting the patient to rinse the
mouth for 60 seconds with a quantity of phosphate buffered saline,
which is returned into a universal container. A small sample is then
plated onto Sabouraud medium and the growth expressed as colony
forming units/ml of rinse.
2.6.1 Primary culture media
In 1896 Sabouraud described a peptone-glucose or peptone-maltose medium
as suitable for the growth and isolation of Candida sp. Sabouraud's medium
has a pH of less than 6, so it suppresses many of the commensal oral
bacteria. Additional suppression can be obtained by adding an antibiotic such
as chloramphenicol or streptomycin. Once inoculated Sabouraud culture
plates are then incubated at 37° C for 2-3 days after which time positive
cultures will show cream coloured, smooth or rough convex colonies.
A variety of other mediums with chromogenic components have been used to
help distinguish between the various species of Candida on primary isolation.
CHROMagar is a new commercial chromogenic medium, which is suitable for
initial differentiation between C.albicans, C.krusei, C. tropicalis and C.
parapsilosis. The addition of an antibiotic by the manufacturers suppresses
bacterial growth.
2.6.2 Morphological tests
• Direct microscopy - A sample is stained with the Gram stain which if
positive will show the characteristic rounded or oval budding cells of
yeast blastospores (yeast form) with or without hyphal phase. The
blastospores can be distinguished from bacteria by their greater size
(3-6 micrometres), oval shape and tendency to produce
pseudohyphae.
• Water mounUwet film - A water emulsion of the sample is mounted on
a slide and the blastospores examined for their average size, shape
and type of budding.
• Potassium hydroxide - Potassium hydroxide is an effective cleansing
agent, eliminating most debris and intensifying the contrast of fungal
structures.
• Germ tube test - this is a rapid screening procedure for differentiating
C.albicans, C.dubliniensis and some strains of C.tropicalis from other
Candida sp. The yeast is lightly inoculated into approximately 1 ml of
sterile serum and incubated for 2-2.5 hours at 37°C. After incubation
suspensions are placed on a glass slide mounted under a cover slip
and examined for the presence of germ tubes. A germ tube is
filamentous, cylindrical outgrowth from the yeast cell with no
constriction at its base.
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• Chlamydospore formation - Chlamydospore formation is a property
peculiar to C.albicans and very rare in isolates of C.tropicalis and
C.stellatoidea. The chlamydospore has been defined as a thick-walled
non-deciduous intercalary or asexual spore formed by a rounding off of
a cell or cells. They are thought to be dormant growth forms produced
under conditions of nutrient depletion.
2.6.3 Physiological tests
Carbon and nitrogen assimilation tests -This test assesses the ability of a
particular yeast isolate to assimilate a specific carbohydrate as its sole carbon
source.
Carbohydrate fermentation -This test is useful for differentiating between
Candida. However it is less sensitive and therefore less dependable than the
assimilation test.
There are rapid commercial systems, which offer a high accuracy of
identification. The API 20C system is the one most widely used.
2.6.4 Strain differentiation within Candida
• Serotyping - typing according to the antigenic characteristics of their
cell walls. There are two serotypes of C.albicans, serotype A and B.
• Biotyping - typing according to biochemical characteristics, where a
variety of proteinases and lipases are used to distinguish between the
biotypes. In 1980 Odds described a set of nine tests that together
permitted identification of 512 potential biotypes. These tests
comprised of; acid and salt tolerance test, proteinase production, two-
resistance tests and four assimilation tests.
2.7 Histological appearance or oral candidosis
Histologically the pseudomembranes seen in oral candidosis consist of a thick
surface zone of sloughed epithelial cells, fibrin, food debris, leucocytes,
bacteria and Candida sp. mainly in the hyphal phase. The
pseudomembranous plaques are caused by the invasion of the superficial
epithelial cells by candidal hyphae along with a proliferative epithelial
response. Neutrophils can be observed throughout the epithelium in particular
at the junction with the glycogen rich zone where microabcesses form. In
chronic atrophic candidosis the epithelium is acanthotic rather than atrophic
and the oedema of the superficial epithelium has a chronic cellular infiltrate.
Ultramicroscopic preparations shows that yeast cells are often partially
enclosed within phagocytic invaginations of epithelia cells. Six hours after
epithelial infiltration, hyphae and yeast cells can be found in submucosal
tissue.
Some reports have described a granulomatous response with non-C.albicans
species including C.glabrata.
These histological features are significantly altered in immunodeficiency
where there is frequently a diminished or even absent cellular infiltrate but
with increased oedema and tissue necrosis.
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2.8 Antifungal agents
A range of anti-fungal medication is available for the treatment of topical and
systemic fungal infections. Although anti-fungal agents such as Amphotericin
B and Nystatin were developed in the early 1950's, the pharmacological
principles of anti-fungal agents are still not fully understood. In addition in vitro
susceptibility testing of anti-fungal agents do not provide consistent and
reproducible results. These factors do not allow for accurate therapeutic
values of anti-fungal agents to be determined.
There are three main categories of antifungal agents available for the
treatment of oral candidosis: polvenes. azoles and disinfectants.
2.8.1 The polyenes
Two polyenes are commonly used for the treatment of oral candidosis;
Amphotericin B and Nystatin. Since their discovery (Amphotericin B in1956)
and Nystatin (1950)]. there have been very few recorded instances of fungal
resistance to these agents. Amphotericin B and Nystatin are frequently used
as Candida infection prophylaxis for AIDS patients.
2.8.1.1 Mode of action:
The precise mechanism of the polyenes on C.albicans is still unclear. They
appear to bind to sterol components in the cell wall of C.albicans forming a
ring complex. This complex prevents the biosynthesis of ergosterol making
the cell wall more permeable. This leads to the impairment of barrier function,
leakage of cellular components, metabolic disruption and as a result the cell
becomes non-viable. In addition the polyenes affect chitin synthetase, which
is required for the secondary cell wall formation.
2.8.1.2 Nystatin
Nystatin has significant anti-fungal properties, although it is only suitable for
the treatment of topical candidosis (212-14). It is highly toxic when
administered parentally. The biological activity of Nystatin is expressed in
international units (lU) as pharmaceutical preparations contain a
heterogeneous mixture of compounds in addition to the major ingredient
Nystatin A1. The anti-fungal effect of Nystatin is compromised by the diluting
effect of oral fluid and the cleansing action of the oral musculature. It also has
a very unpleasant taste so many preparations (suspension & pastille forms)
contain flavouring and sucrose to make the medication more palatable. A
suspension form is commonly used for paediatric patients where compliance
is often difficult to obtain. The effectiveness of topical Nystatin is often
reduced by rapid clearance. Nystatin tablets have no flavouring or sucrose.
Nystatin pastilles do contain these additives and as they are sucked ensures a
longer anti-fungal effect.
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2.8.1.3 Amphotericin B
Despite newer anti-fungal medications Amphotericin B remains the choice for
the treatment of invasive mycoses (215-16). It is available as an intravenous
injection (Fungizone) and as a topical application. Amphotericin B, unlike
Nystatin, can be used for the management of both topical and systemic
Candida infections. It is extremely active against Candida sp. and resistance
is rare.
Amphotericin B binds avidly to ergosterol a major sterol component of the
fungal but not human cell membrane. Low concentrations result in
permeability of the cell with leakage of intracellular components, most
commonly measured as a loss in intracellular potassium.
Amphotericin B is not metabolised but accumulates in lipid rich tissues
throughout the body. For several months small amounts of amphotericin Bare
excreted into the urine and small amounts also appear in the bile.
Conventional amphotericin B has many side-effects, the mechanism may be
related to the ability to release prostaglandins or tumour necrosis factor from
phagocytes.
2.8.2 Azoles
The azole antifungals are a diverse group of compounds administered by
topical and intravenous routes. They act by inhibiting the synthesis of
ergosterol. They target the cytochrome P450 dependant enzyme, lanosterol
14 alpha demethylase. This enzyme demethylates lanosterol in the pathway
that leads to the formation of ergosterol, one of the building blocks of the
cytoplasmic membrane. They are divided on the basis of their chemical
structure into imidazoles (clotrimazole, miconazole and ketoconazole) and
the triazoles (fluconazole and itraconazole)
2.8.2.1 Fluconazole
Fluconazole is a water-soluble triazole derivative. A key feature of this drug is
its high absorption from the gastrointestinal tract regardless of stomach acid
or food content. In contrast to ketonazole and itraconazole most of the drug is
not protein bound and is excreted in an inactive form in the urine. Children
have a more rapid clearance of fluconazole than do adults.
Azoles are considered to be teratogenic and birth defects following
administration of fluconazole have been reported.
2.8.3 Ajoene and Allicin
These are natural compounds found in the herb garlic. The fungistatic and
fungicidal properties of garlic have been recognised for many decades (217-
226). The growth of a micro-organism, synthesis of proteins, nucleic acids and
lipids is hampered by garlic, as is cell respiration. Garlic has been shown to
have synergism with Arnphoterlc.n B.
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2.8.4 Antiseptics
A variety of antiseptic agents are available and licensed for anti-microbial use
in the oral cavity. Chlorohexidine gluconate, either as a mouthwash (0.1 % or
0.2%) or spray is used in the treatment of oral candidosis. The mechanism of
anti-fungal activity is not clearly understood however it appears to interfere
with cell wall synthesis and organisation (227-31).
2.8.5 Anti-fungal resistance
Fluconazole resistance has been identified in Candida infections, primarily in
AIDS patients with oropharyngeal candidosis (232-4). There are several
mechanisms for this resistance. With fluconazole therapy the susceptible
population is initially eradicated and the more resistant population fills the
void. The resistant organisms may be inherently resistant to fluconazole (e.g.
C.kruse/) or resistance may develop during therapy (57,235-38). In this latter
instance several reasons can explain the decrease in susceptibility of the
fungus. There may be an alteration in the target enzyme, cytochrome P450 so
that the azole cannot bind to the enzyme resulting in the lack of inhibition.
Fungi exhibiting this feature usually demonstrate cross-resistance to all
azoles. Another potential explanation for this resistance is either decreased
influx or increased efflux so that intracellular concentrations of the drug are
decreased. Finally a general increase in the amount of cytochrome P450 in
the cell can compensate for the inhibitory effects of the antifungals and
ergosterol synthesis sufficient to maintain growth.
Studies have revealed the presence of genes that code for multi drug
transporters, which actively pump the antifungal drug out of yeast cells
(239,240). These genes CDR1 (Candida drug resistance) and CaMDR1
produce well-characterised transporter molecules coding for a protein that
belongs to the ABC transporter family (241-42). Increased levels of CDR1 and
CaMDR1 encoded RNA have been reported in azole resistant C.albicans
isolates (242). Also the sterol composition of the fungal plasma membrane is
altered thus reducing the uptake of the antifungal agent into the cell.
2.9 HIVand Tuberculosis
2.9.1 Tuberculosis
In developed countries adult and paediatric tuberculosis (TB) is a relatively
minor problem, both in terms of absolute numbers and the proportion that TB
represents in terms of the national caseload (rates for children 0-14 years will
usually be less than 5/100,000). In developing countries childhood rates may
exceed 200/100,000. The case load of paediatric TB may rise to more than
40%, particularly high incidence areas such as the Western Cape region of
South Africa. The incidence of TB has been exacerbated both directly and
indirectly by the HIV/AIDS pandemic. In the Western Cape the 2001 figure is
500/100,000 with some commentators predicting a national rate of
2500/100,000 by the year 2005.
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2.9.2 Microbiology
The causative organism of TB is a member of the genus mycobacterium. This
genus consists of 60 species, which can be classified either according to
growth rates (fast or slow) or their ability to be pathogenic in man and animals.
Some species are obligate pathogens (e.g. M.leprae or M. tuberculosis) while
others are environmental saprophytes which may cause specific / non-specific
opportunistic diseases in animals and man. Others, also environmental
saprophytes, may rarely or never cause disease.
The mycobacterium organism is a non-motile, non-sporing rod. It is an
obligate aerobe, grows and metabolises slowly and can survive in
macrophages. Despite investigation no single determinant of virulence has
been discovered in the mammalian tubercle bacilli. It appears that the
virulence is in part due to the aolllty of mycobacterium to survive within the
macrophages and that some more virulent strains are able to modify the
immune response of the host, so damaging the host rather than the
mycobacterium itself. It has the ability to remain dormant in apparently healthy
individuals and while the precise mechanism is unknown may be due to
metabolic dormancy or a slow rate of replication.
The primary characteristic of the genus mycobacterium is the complex, lipid
rich, hydrophobic cell wall. Another property resulting from the unusual cell
wall is its ability to retain colour imparted by arylmethane dyes following
treatment with weak acids. For this reason mycobacterium are often referred
to as 'acid fast bacilli'.
2.9.3 The HIV infection
History
The acquired immunodeficiency syndrome (AIDS) was first recognized in
1981 and has since become a major worldwide pandemic. AIDS is caused by
the human immunodeficiency virus (HIV). By leading to the destruction and/or
functional impairment of cells of the immune system, notably CD4+ Tcells,
HIV progressively destroys the body's ability to fight infections and certain
cancers.
An HIV-infected person is diagnosed with AIDS when his or her immune
system is seriously compromised and manifestations of HIV infection are
severe. The U.S. Centre for Disease Control and Prevention (CDC) currently
defines AIDS in an adult or adolescent age 13 years or older as the "presence
of one of 26 conditions indicative of severe immunosuppression associated
with HIV infection, such as Pneumocystis carinii pneumonia (PCP), a
condition extraordinarily rare in people without HIV infection". Most other
AIDS-defining conditions are also "opportunistic infections" which rarely cause
harm in healthy individuals. A diagnosis of AIDS also is given to HIV-infected
individuals when their CD4+ T-cell count falls below 200 cells/cubic millimetre
(mrrr') of blood. Healthy adults usually have CD4+ T-cell counts of 600-
1,500/mm3 of blood. In HIV-infected children younger than 13 years, the CDC
definition of AIDS is similar to that in adolescents and adults, except for the
addition of certain infections commonly seen in paediatric patients with HIV.
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HIVepidemiology
At the end of 2000 an estimated 36.1 million people worldwide, 34.7 million
adults and 1.4 million children younger than 15 years, were thought to be
living with HIV/AIDS. Through 2000, cumulative HIV/AIDS-associated deaths
worldwide numbered approximately 21.8 million, 17.5 million adults and 4.3
million children younger than 15 years.
Among the many criteria used over the years to prove the link between
putative pathogenic (disease-causing) agents and disease, perhaps the most
often quoted are Koch's postul. tes, which were developed in the late 19th
century.
Aetiology of HIV
HIV is an RNA virus and is more specifically part of the lentivirus subgroup.
The virus is more than 100nm in diameter and both HIV-1 and HIV-2 have
cone shaped cores consisting of p25 protein, which makes up the cuspid.
Inside this cuspid lie two identical strands of RNA. The Gp120 protein,
referred to the external envelope protein, lies on the outer surface of the virus
particle and contains the binding site for immune cells as well as the domain
for the neutralising antibodies.
Infection with the human immunodeficiency virus type 1 (HIV-1) results in
progressive loss of immune function marked by depletion of the CD4+ T-
lymphocytes, leading to opportunistic infections and malignancies
characteristic of AIDS. Although both host and viral determinants influence the
rate of disease progression, tra median time from initial infection to the
development of AIDS among untreated patients, ranges from 8 to 10 years.
The clinical staging of HIV disease and the relative risk of developing
opportunistic infections historically relied on the CD4+ T-Iymphocyte counts.
Although more recent studies have shown the importance of viral load
quantification in determining the rate of disease progression, it is still useful to
categorize HIV disease stage on the basis of the degree of immunodeficiency:
early disease (CD4+ > 500 celts/ml), mid-stage disease (CD4+ between 200
and 500 cells/ml), and end-stage disease (CD4+ < 50 cell/ml).
Pathogenesis of HIV
It is generally agreed that HIV is the primary causative agent of AIDS initiating
and propagating the pathogenic process.
Various mechanisms of transmission have been identified including sexual
contact, intravenous drug use, blood transfusions, vertical transmission, and
more contentiously transmission via oral fluid.
Cells that are infected by the H:V include CD4+ helper cell, macrophages /
monocytes, dendritic cells and CD4- cells. The host reacts to the HIV infection
via a humoral response; neutralising antibodies, antibody dependant
cytotoxicity, enhanced antibodies, complement-fixing antiviral antibodies, and
also via a cell mediated response; cytotoxic Natural Killer cells, CD4+ cells
and CD8+ cells.
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Clinical aspects of HIV
There are a number of systems to categorize the HIV infection. One is based
on clinical symptoms, while another preferred by the CDC in Atlanta USA,
uses the immunopathogenesis of HIV, classifying the disease according to the
CD4+ levels in the blood.
Oral manifestations of HIV infection.
Oral lesions were amongst the earliest lesions described in patients with
AIDS. In 1992 a classification of oral lesions associated with HIV was
published after a meeting of the EC clearing house on Oral problems related
to HIV infection. The classification divides the lesions into three groups. Group
1 are those strongly associated with HIV infection, group 2 those less
commonly associated with HIV infection, and group three those lesions seen
in HIV infection. Oral lesions are often early features of the HIV infection and
are thought to predict progression.
Treatment of HIV
The management of HIV is aimed at delaying the progression of HIV,
prevention of opportunistic infections and early recognition and treatment of
infections and neoplasms. The p.imary focus of HIV medication and treatment
is to delay the progression of immunodeficiency, by means of antiretroviral
therapies. Anti retroviral therapy is based on a number of different drugs,
which affect different areas of HIV development. Vaccines against HIVare
also being investigated.
2.9.4 Tuberculosis I HIV co-infection
The mutually deleterious interaction between HIV/AIDS and TB was
recognised in adults soon after the scope of the HIV epidemic became evident
(243). The interaction between TB and the HIV infection / AIDS has been
responsible for substantial increases in the incidence of TB in all the sub-
Saharan African countries and has appropriately been termed the 'cursed
duet' (244-45).
In populations where there is a high incidence of infection due to
M.tuberculosis, the clinical appelrance of TB disease is one of the first signs
of a deteriorating immune status in patients in HIV-infected individuals (246).
There is also a fundamental difference in the development of TB disease
between HIV-infected adults and children. In developing countries adults will
frequently have been infected with TB before acquiring the HIV infection.
Evidence suggests that the picture is different in children where the children
are almost always acquire the HIV infection neo-natally and are only later be
infected with TB.
It is now apparent that the development of TB precipitates a more rapid
decline in cellular immunity than might otherwise occur and accelerates the
course of the HIV infection. The converse situation of this scenario is also true
i.e. that that newly acquired TB infection will progress more rapidly in the
presence of the HIV infection.
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The presence of multiplying M. tuberculosis in monocytes and macrophages
enhances HIV-1 multiplicaticn and is associated with increased
concentrations of TNF alpha 'and beta-2 microglobulin. The associated
destruction of the CD4 subset of lymphocytes in its turn promotes the
development of AIDS complex and further susceptibility to opportunistic
infections.
2.9.5 The Interaction between Nutrition, Tuberculosis and the HIV
infection
The relationship between nutrition and TB is well documented. This
relationship is now further complicated by the interaction between the HIV
infection / AIDS and TB as both these diseases are closely associated with
the development of various forms of protein-energy malnutrition (247-50).
There are differing opinions as to the importance of nutrition in the
pathogenesis of TB. There are several mechanisms by which TB could
influence nutrition. Firstly TB will often be associated with increased
circulating concentrations of TNF, which will contribute to increased
catabolism in order to provide th.smaterials to combat the infection. Secondly
a significant number of children with primary TB will also have involvement of
the abdominal lymph nodes as a result of retrograde spread of the
mycobacteria. This development will not lead to the development of overt
abdominal TB in most cases but could, none the less, compromise the
lymphatic drainage of the gut and so lead to malabsorption of drugs and
nutrients. Thirdly, overt abdominal TB in its various forms may be associated
with the malabsorption of nutrients and drugs as well as loss of nutrients.
Deficiencies in cellular immunity are probably the commonest cause of
increased susceptibility to TB but protein-energy malnutrition together with
deficiencies of individual vitamins and micronutrients may also be implicated.
Vitamin D and its metabolites fulfil an important role in cellular immunity.
2.9.6 Nutrition, the HIV infection and Opportunistic infection
Malnutrition is one of the major complications of HIV infection / AIDS and is a
result of many factors including the HIV infection itself, HIV/AIDS associated
complications and opportunistic infections especially those affecting the gut.
Studies suggest that nutrition may be an important determinant of the
progression of AIDS associated disease.
The oral manifestations of HIV have been well documented with oral
candidiasis one of the most common and significant findings (251).
Interestingly studies conducted into pulmonary TB in HIV positive patients
have also reported a high incidence of oral and oro-pharyngeal candidiasis
(251).
2.9.7 The Oral Cavity, Tuberculosis and the HIV infection lAIDS:.
Tuberculous lesions of the oral cavity are an uncommon manifestation of the
disease, usually co-existent with pulmonary TB (252-6). It is estimated that
oral lesions are seen in 0.05% to 1.5% of the patients with TB. Direct
inoculation of the oral mucosa is thought to be rare as the intact squamous
epithelium of oral mucosa is relatively resistant to penetration by
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Mycobacterium tuberculosis. Oral tuberculous lesions usually present as non-
specific lesions. These can take the form of irregular ulceration or a discrete
granular mass, most commonly on the tongue or gingiva.
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Chapter 3
Aim of the study
The aim of the study was to:
a. assess the change in the oral carriage of Candida species in patients co-
infected with HIVand TB before and after antifungal treatment,
b. to record the sensitivity of Candida sp. isolated in the study population
against a variety of antifungal agents.
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Chapter 4
Methods and Materials
4.1 Sample Group
Twenty-nine patients co-infected with HIVand TB were studied at the
Brooklyn Chest Hospital (BCH), Cape Town, South Africa from July 2000 to
March 2001.
The patients had been referred to the BCH from satellite health clinics and
other hospitals in the Western Cape for the treatment and management of TB.
The sample group included cases of both pulmonary and extra-pulmonary TB.
The subjects were between 16 and 40 years of age, had laboratory- confirmed
HIV sero-conversion, and a diagnosis of TB made by a qualified medical
consultant, using chest X-rays, sputum microscopy (smear positive test for
Acid Alcohol Fast bacilli) and bacterial culturing (257). All patients selected for
this study had been diagnosed as being HIV sero-positive prior to admission.
Details of the place and date of HIV testing were included in each patient's
referral to the BCH.
On admission to the BCH the patients were examined by the resident medical
doctor who requested further tests where required and prescribed the
appropriate TB treatment regime as detailed in the government national TB
guidelines.
4.2 Oral Medicine clinical exarnlnatlon and sampling
The cohort for this study was selected from consecutive new admissions to
the Brooklyn Chest Hospital. The examiner outlined the objectives and
purpose of the study to each prospective patient. He also gave a detailed
verbal explanation as to what participation the study would involve
(*translation where appropriate). In the presence of a witness and with the
patient's verbal agreement, a written information sheet and separate consent
form was provided and signed by the patient (English, Afrikaans, Xhosa forms
used as appropriate).
A qualified specialist in Oral Medicine carried out all the clinical examinations.
The examiner had a standardized sterile examination kit for each patient,
which included a dental mirror, dental and CPITN probe, tweezers, cotton
wool, gauze. Each examination took place in the surgical theatre of the BCH
to ensure the highest levels of cross infection control.
The mouth and related structures of each study participant were examined. A
descriptive record was made of ,til oral and peri-oral lesions. A lesion was any
pathological or traumatic discontinuity of tissue or loss of function of a part.
Diagnosis of the oral lesions was based on their clinical appearance and each
lesion classified according to E.C. Clearing House criteria (258).
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The medical history of each volunteer was obtained from the BCH patient
records, which included details of current and past illnesses and medication,
social history giving details of previous and present use of tobacco, alcohol
and other drugs, and details of whether the patient was taking part in any
other clinical studies.
The findings of the oral/perioral examination were recorded on the Study
Examination Form (see Appendices). The Periodontal Index of Treatment
Needs (CPITN - WHO 1982) was used to assess the periodontium (259).
Photographs of unusual oral lesions were also taken.
After the oral examination each subject was asked to rinse their mouth with 5
millilitres (ml) of sterile phosphate buffered saline solution from a sterile
universal container. Each subject rinsed for one minute before expectorating
the oral fluid-buffer solution into the same container, which was immediately
sealed and placed in a cooler-box for transportation. The same examination
and rinse procedure was followed at the one month and three month
inspections.
The diagnosis of oral candidosis in this study included the presence of clinical
changes consistent with oral candidosis, the presence of either the yeast
form, hyphae or pseudohyphae in the oral samples from the affected area,
and a high yield (>400cfu/ml) of Candida sp. grown in cultures from the lesion
(260-1).
4.3 Processing of Samples
4.3.1 Oral Candida sp. isolation
An initial trial carried out by Dr Basson at the Oral and Dental Research
Institute, found that it was necessary to dilute the oral fluid rinse sample by 10-
2 to ensure adequate separation of colonies for enumeration after 48 hours.
After transportation to the labo-story 100 microlitre (IJl) of each rinse was
added to a sterile glass pot containing 900IJI of sterile phosphate buffered
saline (PBS). This solution was gently mixed for one minute and a 100IJI
aliquot was plated onto CHROMagar. The oral fluid/buffered phosphate saline
mixed liquid was spread over the plate using a sterile right-angled glass rod
and incubated aerobically for 48 hours (hr) at 370C.
The plate was assessed for the presence of yeast colonies after 48 hrs.
Candida colonies were counted on CHROMagar plates and reported as
colony-forming units per millilitre (cfu/ml) of rinse (Fig 1).
4.3.2 The phenotypic characteristics of Candida sp. isolates
Each morphologically and chromogenically distinct colony identified on the
CAC plates was photographed and described (Fig 2 - Fig 12). A single
sample from each different colour-coded colony was taken and streaked onto
Sabouraud's dextrose agar plate to obtain single species culture. Each
Sabouraud plate (Oxoid) was then incubated for 48 hrs at 37°C. These sub-
cultured colonies were used for all subsequent isolate identification tests.
These tests included sugar assimilation profile, germ tube test,
chlamydospore production, growth at 45°C, beta glucosidase test and anti-
fungal sensitivity tests (262).
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40
All the original CHROMagar plates were kept refrigerated at 4 =c for three
weeks, and at which time a further inspection and examination of the colonies
was carried out.
Fi~ure1. A CHROMagar plate showing five Candida species isolates:
Green colony; Candida albicans, Small white colony; Candida
parapsilosis, Pink/purple colony; Candida kruset. Light purple colony;
Candida glabrata and deep purple colony; Candida tropicalis
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Figure 2. Candida krusei
Figure 4. Candida albicans
(light green colony)
Figure 3. Candida tropicalis (left);
showing its distinctive 'halo'
in CHROMagar
Figure 5. Candida dubliniensis
(dark green colony)
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Figure 6. Candida parapsilosis
Figure 8. Candida Parapsilosis
Figure 11. Candida glabrata
Figure 7. Candida parapsilosis
Figure 9 Candida Parapsilosis
Figure 12. Candida glabrata
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4.3.3 Identification of Candida sp.
4.3.3.1Germ tube test
The germ tube test was performed according to the method described by
Buckley (263). 5001J1of fetal calf serum was inoculated with a small sample
from the subculture of each morphologically and chromogenically different
colony and incubated at 370C. After three hours a drop of the inoculum was
examined under a light microscope using phase contrast microscopy. The
presence of germ tubes identified the isolate as C.albicans or C.dubliniensis.
4.3.3.2 Identification of Candida sp. using a sugar assimilation -
disc diffusion test
A small sample from each morphologically and chromogenically different
colony was plated on a yeast nitrogen base medium (Sigma, St Louis, MD,
USA). A concentrated sterile solution of dextrose, mannose, maltose,
rafinose, lactose and sucrose was prepared.
A quantity of 5 mm discs of absorbent paper were sterilised in a dry oven at
160 0 C for two hours. Each 5 mm disc was impregnated with one of the
selected concentrated sterile sugar solutions and placed a suitable distance
apart on the medium. The prepared plates were incubated for 48 hours at
370C and then examined for evidence of sugar assimilation.
4.3.3.3 The identification of Candida sp. with Auxanograms
Each morphologically and chromogenically different colony was tested for its
substrate assimilation profile using the API 1032C yeast identification system
(bioMerieux, France). The API ID 32 C is an identification system for yeasts
using standardised and minla.urlsed assimilation tests with a specially
adapted database. The 1032C system consists of 32 cupules, each containing
a dehydrated carbohydrate substrate. A semi solid chemically defined,
minimal medium is inoculated with a suspension of the colony to be tested.
After 24-48 hours of incubation at 37°C, growth in each cupuie is detected by
the ATB instruments or by visual reading. Identification is obtained by referring
to the Analytical Profile Index or with the corresponding identification software.
4.3.3.4 Tests for C.dubliniensis
Those isolates that tested positive for germ tube formation were each
examined for chlamydospore production, growth at 450C and beta
glucosidase activity.
One sample was incubated on 1% rice-cream-1% Tween 80 agar (Sigma, St
Louis, MO, USA) at 25 °c and examined for the presence of chlamydospore
after 48h. A second sample was sub-cultured as a single streak onto two
separate plates of Sabouraud dextrose agar (Oxoid). One plate was incubated
at 37 °c and the other at 45 oe for 48 hr. The streak on each plate was
assessed after 24h and graded according to percentage growth of the
inoculated sample (Fig 13).
A group of intracellular enzymes called glucosidases are found in great
number of bacteria and fungi. One enzyme, Beta-O-glucosidase permease, is
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located on the cell wall and is responsible for the transport and accumulation
of specific substrate to within the cell.
C.dubliniensis unlike C.albicans does not produce intracellular beta
glucosidase. To test for beta glucosidase activity, a third sample from each
isolate that tested positive for germ tube formation was inoculated onto Brain
Heart Infusion medium (Difco Laboratories, Detroit, MI) and incubated for 24
hours at 37°C. A good loop of the resultant colony was taken and suspended
in two ml of sterile PBS. One ml of this culture was centrifuged at 16,OOO-xg
in a micro-centrifuge. The supernatant was extracted and the remaining cells
were re-suspended in 1001-11of 0.1M sodium acetate at pH 5.5, containing
0.1% methylumbelliferyl-beta-glucosidase (Sigma, St Louis, MO, USA). Glass
beads were added, followed by mixing twice on a bench vortex mixer for one
minute and then centrifuged again for two minutes at 16,OOO-xg in a micro-
centrifuge. The supernatant was transferred to a new Eppendorf tube and
once more centrifuged at 16,000-x g. The resulting supernatant was
transferred to the wells of a micro-dilution plate, allowed to stand for fifteen
minutes at room temperature, and then examined on a UV transilluminator of
302 nanometers. Strains positive for beta glucosidase produced a bright
fluorescence indicating C.albicans. The remaining strains that did not
fluoresce were classified as C.dubliniensis.
4.4 Antifungal sensitivity tests on Candida sp. isolates
This study used two methods to measure the sensitivity of antifungal agents
(listed below) against all the Candida sp. identified from the patients
participating in this study.
The anti-fungal agents used were:
1. Fluconazole
2. Amphotericin B
3. Nystatin
4. Ajoene
5. Allicin
The E-Test antifungal sensitivity test kit is produced by AB Biodisc of Sweden
and is accredited for research and investigational use. E-Test strips were
used to measure sensitivity for Fluconazole and Amphotericin B. Studies have
shown that the Minimum Inhibitory Concentrations (MIG) obtained with the E-
test kit correlate with both reference agar and dilution broth procedures.
Since no commercial test for Nystatin sensitivity is available, the disc diffusion
method was used to quantify anUungal sensitivity (Fig 14,15,16).
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Figure 13. Growth of Candida dubliniensis at 450C (left) and 37°C (right)
Fig 14. Ajoene dissolved in sterile water
Figure 15 shows anti-fungal activity
of 100,000 and 10,000 units of
Nystatin.
Figure 16 shows anti-fungal activity of
100,000 and 10,000 units of Nystatin,
allicin and 1mg/ml of Ajoene.
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Ajoene and Allicin are compounds found in garlic that have been identified as
possessing anti-fungal properties. Professor Roger Hunter of the Department
of Physical Chemistry at the University of Cape Town has determined the
structure and composition of these two compounds. The Ajoene used for
antifungal sensitivity testing was a chemically pure sample of Ajoene
synthesised by Prof Hunter. The Allicin used in the antifungal sensitivity tests
was obtained from the natural i.erb. Prof. Hunter provided both samples of
Ajoene and Allicin used for the anti-fungal sensitivity testing in this study. A
disc diffusion method was used to quantify antifungal sensitivity (Fig
14,15,16).
4.4.1 Antifungal tests
One operator prepared all the items required for the E-tests and disc diffusion
measurements. The same operator interpreted the results and noted the
Minimum Inhibitory Concentration (MIC) values
The instructions and procedures for the E-test kit were followed and allowed
for straight-forward interpretation of results.
4.4.2 E-Test
The construction of a Nephelometer was required as part of the E-test
investigation.
To prepare a Nephelometer (0.5 MacFarland solution), 0.05 ml of a 1%
solution of chemically pure barium chloride (Merck) was put into a tube and a
quantity of a 1% chemically pure sulphuric acid solution (Merck) sufficient to
make a total volume of ten ml was added. This tube was then sealed.
Ten ml of sterile saline (0.85% sodium chloride) was added to a new tube,
which had the same size and dimensions as that used for the Nephelometer.
An amount of each isolate was added to this tube, which produced the same
turbidity as that of a 0.5 MacFarlands. Both the tube containing the isolate and
the 0.5 MacFarland tube were shaken well prior to comparison. The resultant
tube of a 0.5 MacFarland inoculum suspension was sealed.
A sterile plate of Sabouraud dextrose medium (Oxoid) with a depth of 4.0 +/-
0.5 millimetres was prepared. A sterile non-toxic swab (not too tightly spun)
was dipped into the inoculum suspension and rolled against the base of the
plate. The entire base of the plate was swabbed evenly and in three
directions. Ten to fifteen minutes was allowed for the excess moisture to be
absorbed.
Using forceps the E-test strips tor Amphotericin B and for Fluconazole were
placed on the dry surface of the plate ensuring the MIC scale was facing
upwards and the concentration maximum facing towards the periphery of the
plate.
4.4.3 Anti-fungal sensitivity testing for Nystatin, Ajoene and Allicin
A disc diffusion technique was used to assess the anti-fungal susceptibility of
the commercial anti-fungal agent Nystatin and natural derived garlic
components Ajoene and Allicin. A preliminary sensitivity test was first
performed using Nystatin, Ajoene and Allicin to gauge anti-fungal sensitivity
ranges (Fig 15).
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As described for the E-tests, solutions of Nystatin, Ajoene and Allicin were
prepared in a range of concentrations. One five mm discs was impregnated
with each of the solutions and the discs were placed a suitable distance apart
on the medium. The prepared plates were incubated for 48 hours at 370C and
then were examined for evidence of anti-fungal activity.
The resultant values were used to determine the sensitivity range of each anti-
fungal agent to be used in the subsequent test.
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Chapter 5
Results
5.1 Sample group
A total of 50 HIV positive patients who were admitted to the Brooklyn Chest
Hospital (BCH) between July and December 2000 for treatment of
Tuberculosis (TB) were eligible 'or this study. There were 29 females (58%)
and 21 males (42%).
Only 29 patients remained as inpatients at the BCH for the three-months
assessment period. This group of patients were used for the study. Of the 21
patients who were excluded from the study six were discharged or referred to
other institutions and 15 (8 female and 7 male) died. The author was unable to
establish if there was any common cause of death as in many cases hospital
records only noted time of death. Various factors may have contributed to the
demise of some patients including nutritional status, HIV viral load and
severity of the TB. The study therefore included 18 (62%) females and 11
(38%) males. The average age was 33.9 years with the female average 33
years and the male average 35.3 years.
5.2 Oral lesions
5.2.1 Extra-oral lesions
The most common site of lymphadenopathy was in the cervical node group,
predominantly on the right side (Fig 17). Right and bi-Iateral cervical
lymphadenopathy showed a constant prevalence on admission and at three
months. There was a decrease in the prevalence of left side cervical node
lymphadenopathy at three months (Fig 17). A statistically significant number
of patients presented with only right-sided cervical lymphadenopathy. No
other extra-oral signs of the HIV infection / AIDS such as parotid swelling /
uni-Iateral or bi-Iateral swelling of the major salivary glands were observed. No
lesions indicative of lupus vulgaris, scrofuloderma or orificial tuberculosis were
observed.
Figure 18. shows an example of a peri-oral lesion seen on admission. The
lesion was asymmetrical, discrete, localised and crusted, indicating it could
possible be a recurrent herpes simplex virus infection. None of the study
patients showed perioral lesions at the three months examination.
Thiacetazone is occasionally used in TB therapy, and is associated with an
adverse reaction leading to skin lesions. This drug was not used in the TB
management of the study populetien.
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Fig 17. Frequency and location of lymphadenopathy.
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Figure 18. Recurrent HSV infection involving
the vermillion border and skin
of peri-oral tissue.
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5.2.2. Intraoral lesions
Intra-oral lesions were observed in 96% of patients included in this study. All
categories of oral lesions showed a decrease over the three months study
period. The results (Fig 19) indicate that oral candidosis was a significant and
persistent oral lesion, both on acnission (96%) and after three months (93%).
Linear gingival erythema (LGE, Figs 20,21) was the second most common
lesion observed both on admission (31%) and at three months (24%). Angular
cheilitis was observed in 24% of patients on admission but had decreased to
7% at the three months (Figs 22,23).
Lip ulceration including the vermillion border was present in 13% of patients
on admission decreasing to 3% at the three months assessment. Severe
haemorrhagic crusting of the lower lip was observed in 14% of patients both
on admission and at the three months (Fig 24).
At the initial oral examination one patient presented with an unusual lesion on
the dorsal surface of the tongue (Figs 25,26). When first observed on
admission it was a well-circumscribed, flat, homogenous lesion with a smooth
surface exhibiting no surface fissuring or pigmentation. The borders of the
lesion were well demarcated by a prominent deep fissure. Subsequently the
lesion was noted to have 'fractured' with several fissures appearing to run
through the dorsal surface, dividi:1g it into smaller islands, all of similar texture
and appearance. No biopsy or additional investigations could be carried out
due to the patient's medical status. A smear was taken from the dorsal aspect
of the lesion. The pathologists report described the presence of abundant
fungal hyphae. The patient also presented as a complex management case
with regard to TB, suffering from several episodes of drug hypersensitivity and
exhibited a poor response to TB medication.
5.2.3 Oral candidosis
The most common form of oral candidosis on admission was the
pseudomembranous type, which occurred in over 50% of the study population
(Fig 27). At three months an increase in the erythematous type and reduction
in pseudomembranous type of oral candidosls was observed (Fig 27). There
appeared to be little significant change in the prevalence of the mixed
pseudomembranous & erythematous type of oral candidosis (Fig 27).
Figures 28 and 29 show the distribution of types of oral candidosis on five
surfaces of the oral cavity. 'l here was a marked increase in subjects
presenting with the pseudomembranous type of oral candidosis associated
with the floor of the mouth over the study interval. All other surfaces of the oral
mucosa examined showed a reduction in the pseudomembranous type of oral
candidosis. There was an increase in the erythematous type of oral
candidosis associated with all surfaces of the oral mucosa examined over the
study period. No significant change was observed in the mixed
pseudomembranous I erythematous type of oral candidosis on the surfaces of
the oral cavity over the study period.
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Column 1: Oral candidosis (all clinical forms) = 96/93%
Column 2: Linear gingival erythema = 31/24%
Column 3: Angular cheilitis = 24/ 7%
Column 4: Lip ulceration = 13/ 3%
Column 5: Hairy leucoplakia = 10/ 3%
Column 6: Kaposi sarcoma = 3/ 3%
Column 7: Lip with 'moth eaten' appearance = 3/38%
Fig 19. Percentage of patients with specific oral lesions identified at examination;
on admission (blue) and at three months (red). See Fig 27 for further
subdivision of oral candidosis.
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Figure 20. Linear Gingival Erythema
Figure 22. Angular Cheilitis
Figure 21. Generalised Linear Gingival
Erythema
Figure 23. Angular Cheilitis
Figure 24. Severe haemorrhagic crusting of the lower lips
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Fig 26. An unusual, long standing lesion
associated with the dorsal surface of
the tongue.
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Fig 27. Percentage clinical type of oral candidosis found in oral cavity.
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Fig 28. The distribution of clinical type of oral candidosis within
the oral cavity on admission.
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Figure 29. The distribution of clinical type of oral candidosis
within the oral cavity at three months.
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Over 80% of subjects presented with atrophy of the dorsal aspect of the
tongue, both on admission and at three months (Fig 30).
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.Atrophic &
pseudomembranous
OAtrophic and erythematous
oAtrophic with pseudo &
erythematous
Figure 30. The distribution of the different clinical forms of oral candidasis
observed On the dorsal surface of the tongue on admission and
at three months.
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5.3 Identification of Candida sp.
All light and dark green colonies isolated using CHROMagar medium tested
positive for germ tubes (Fig 4,5). Three white colonies also tested positive for
the germ tube test and further identification using the two sugar assimilation
tests identified these isolates as C.tropicalis (Fig 31).
After the initial examination all the CHROMagar culture plates were kept in a
refrigerator at 4°C for three weeks. At this time a variation in the uptake of
chromogenic medium by the green colonies was noted. The majority of the
light green colonies identified as C. albicans after 48 h had deepened to a
dark green colour. Several of the dark green colonies identified as C.
dubliniensis after 48 h had deepened to an inky black colour (Figs 32,33).
All but one of the isolates tested for beta D-glucosidase activity demonstrated
fluorescence. Several isolates demonstrated poor fluorescence but only those
isolates that showed no evidence of fluorescence were reported as negative
for Beta D-glucosidase activity.
C.albicans isolates that had tested positive for both germ tube formation and
beta D-glucosidase activity grew well at both 37°C and 45 °C. The majority of
isolates showed 100% growth, with only a few isolates exhibiting between
100% and 75% growth. The C.d'Jbliniensis isolate was positive for germ tube
formation but negative for Beta D-glucosidase activity showed no or poor (i.e.
less than 25%) growth at 45°C (Fig 13).
The isolates identified as either dark or light green did not generate hyper
production of chlamydospores in a consistent enough manner to allow for
species identification.
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Figure 31. Green colony: Candida a/bicans
White colony: Candida tropica/is
Figure 32.
A CHROMagar plate after incubation at 4°C for three weeks demonstrates the
differential uptake of chromogenic agent by C. a/bicans (light green) and
C.dub/iniensis (inky blue colony)
Figure 33 Dark blue C.dubliniensis
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5.3.1 Candida species
On admission C.albicans was the most common Candida sp. isolated with
C.tropicalis, C.glabrata, C.parapsilosis, C.dubliniensis and C.krusei isolated in
descending order of frequency (Fig 34). At three months C.albicans was again
the most common Candida sp. isolated, followed in descending order by
C.parapsilosis, C.glabrata, C.tropicalis and C.dubliniensis. These last two
species were identified in equal amounts. C.krusei was not isolated at three
months (Fig 34). The chromogenic characteristic of each Candida sp. isolate
is recorded in Table 1.
The study population demonstrated a general shift towards fewer
combinations of isolates at three months. 50% of subjects had only one
species of Candida isolated from the oral rinse on admission and at three
months (Table 2). There was a 6% increase in subjects showing only one
species at three months (Table 3).
No comment could be passed on the relationship between combinations of
Candida sp. isolated and clinical type of oral candidasis observed.
There was a decrease in the total number of colony forming units over the
three-month study period (Fig 35). Female subjects had the highest Candida
sp. load on admission (expressed as colony forming units per millilitre, cfu/ml)
however they showed the largest decrease over three months (Fig 36). All
Candida sp. isolates demonstrated a decrease in the number of colony
forming units over the three months study period. C.albicans and C.tropicalis
showed the largest decrease over the three months (Fig 37). Subjects
presenting with severe and extensive oral candidasis had values of over 2500
for colony forming units per millilitre (cfu/ml).
It was not possible to establish any correlation between the clinical type of oral
candidasis observed and the Candida sp. isolated from the oral rinse. No
comment could be made on whether a specific species of CtilJpida was
responsible for linear gingival erythema.
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C.albicans C.dubliniensis C.tropicá/is C.parapsilosis C.glabrata C.krusel
Figure 34. Prevalence of Candida species identified in study population on
admission (blue) and at three months (red).
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Table 1. Colony Characteristics of Candida sp. isolated on CHROMagar medium.
Species Colour of Colonies on CHROMagar Appearance
C.albicans Green Smooth, regular
outline
C.dubliniensis Smaller than Candida albicans Smooth, regular
Dark green or blue / green outline
C.glabrata Dark pink / purple Pimpled surface,
with paler edges regular outline
C.krusei Light / pale pink Fluffy, pimpled
surface,
C.parapsilosis White / pale pink smooth surface
C.tropicaJis Blue / deep purple with halo Smooth surface
with distinct bluish
halo in the agar
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Table 2. The pattern of Candida species colonisation in the oral cavity on admission.
Number of species isolated Number of patients (%)
One species 17 (59%)
Two species 9 (31%)
2 (7%)Three species
Four species 1 (3%)
Table 3. The pattern of Candida species colonisation in the oral cavity at three
months.
Number of species isolated Number of patients (%)
No species 2 (7%)
22 (76%)One species
Two species 3 (10%)
2 (7%)Three species
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Fig 35. Mean value of Candida isolates expressed as colony forming
units per millilitre of oral rinse (cfu/ml) identified in study population.
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Fig 36. Mean value of Candida isolates expressed as colony forming units per
millilitre (cfu/ml) identified in male and female patients of the study
population.
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Colony forming
units
C.albicans C.dubliniensis C.tropicalis C.parapsilosis C.glabrata C.krusei
Fig 37. The relationship between Candida species and colony forming units (cfu/ml)
for each Candida species on admission (blue) and at three months (red).
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5.4 Antifungal sensitivity tests of Candida sp. isolates
53.5% of isolates identified on admission had a minimum inhibitory
concentration (MIG) for fluconazole of less than 64 ug I ml, whilst 46.5% had a
MIG of 64 ug/ml or more. At three months 45% had a MIG for fluconazole of
less than 64 ug I ml whilst 55% had MIG's of 64ug/ml or more (Table 4).
A" isolates identified on admission had a minimum inhibitory concentration of
64 ug/ml or below to Amphotericin B. One isolate identified as C.glabrata had
an MIG of above 64 ug/ml at three months. This isolate recorded an MIG of
>256 ug/ml indicating 100% resistance (Table 5).
Nystatin was effective against a" of the isolates at concentrations between
10,000 and 100,000 IU and a high percentage of isolates at less than 10,000
IU both on admission and at three months. No response was recorded below
1000 IU either on admission or at three months (Table 6).
A"icin showed antifungal activity between 0.1 mg I ml and 1mg/ml. The results
of the anti-fungal sensitivity testing with Allicin (1mg/ml) showed that only two
isolates were resistant; both those of C.glabrata. Ajoene demonstrated
variable response to some of the isolates but was not active below 1mg/ml.
Seven isolates identified as C.albicans were susceptible to 1mg/ml of ajoene.
Ethanol showed no antifungal activity against any of the Candida sp. isolated
from the study (Table 7).
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Table 4. Sensitivity of Candida sp. isolates to Fluconazole anti-fungal agent on
admission I three months.
Candida species
C.albicans C.dubliniensis C.tropicalis C.parapsilosis C.glabrata C.krusei
Concentratior
(ug/ml)
0-4 3/1 - - - - -
8-16 3/2 - 1 /0 0/1 - -
24 1 /1 - 1 /0 - - -
32 10/7 1 /0 1 /0 - - -
48 2/3 - - - - -
64 7/10 - 1/0 1 /1 - -
96 2/0 - - 1/0 - -
128 1 /1 - - - - -
>256 0/1 0/1 2/1 0/1 3/2 2/0
Table 5. Sensitivity of Candida sp. isolates to Amphotericin B on admission
I three months.
Candida species
C.albicans C.dubliniensis C.tropicalis C.parapsilosis C.glabrata C.krusei
Concentratior
(ug/ml)
0-0.5 16/15 - 3/0 2/1 1/0 -
0.5 -1 5/6 - 2/1 0/2 1/0 -
1 -1.5 3/4 1 /0 - 1/1 -
1.5 - 3 3/0 - - - - -
3-6 2/1 1 /1 - - - 2/0
>256 0/0 - - - 0/1 -
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Table 6. Sensitivity of Candida sp. isolates to Nystatin on admission
/ three months.
Candida species
C.albicans C.dubliniensis C.tropicalis Ciparapsilosis C.glabrata C.krusei
Concentratior
(lUImi)
100,000 12/9 1 /1 2/1 2/1 0/1 1/0
< 10,000 17/17 - 4/1 0/2 3/1 1/0
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Table 7. Concentrations of antifungal agents Nystatin, Ajoene, and Allicin
dissolved in water and their antifungal effectiveness on admission/at
three months. The symbol +++ denotes a clear zone of 5mm or more
around the impregnated disc, ++ a zone of between 1-5mm and +/-
denotes a unclear but possible zone of 1mm.
Anti-fungal Solvent Concentration Antifungal
agent effect
Nystatin sterile water 100,000 units/ml +++
Nystatin " " 10,000 units/ml +++
Nystatin " " 1000 units/ml -
Allicin " " 1 mg/ml +++
Allicin " " 10JJI/ ml + /-
Ajoene " " 1mg / ml + /-
Ajoene u u 10JJI/ml -
Ajoene " " 0.1 JJI/ ml -
Ajoene " " 50JJI/ ml -
Ajoene " " 20JJI/ ml -
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Table 8. Different concentrations of Ajoene dissolved in ethanol* / water
solution and their antifungal effectiveness. The symbol +++ denotes a clear
zone of 5mm or more arcund the impregnated disc, ++ a zone of between
1-5mm and +/-denotes a unclear but possible zone of 1mm.
Anti-fungal Solution Concentration
Agent agent Antifungal effect
Ajoene Ethanol 1 water 1mg 1 ml + 1-
Ajoene " " 101-111 ml -
Ajoene " " 0.11-111 ml -
Ajoene " " 501-l1/mi -
Ajoene "
..
2Ol-ll/mi -
* An additional test to assess the antifungal potential of ethanol against each of the Candida
species identified on the study, found that ethanol alone possessed no antifungal properties.
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Chapter 6
Discussion
6.1 Oral lesions
Oral lesions occurred in a high proportion of the subjects examined in this
study, both on admission and at three months (Fig 19).
Oral candidosis was the most frequently identified oral infection (Fig 38, 39).
This is consistent with the findings of other studies on the oral manifestations
of HIV (165,264-73). In this study 96% of subjects on admission and 93% at
three months presented with oral candidosis.
Candida sp. and Staphylococcus sp. infection, immune deficiency, mechanical
factors and pernicious anaemia are all implicated in the aetiology of angular
cheilitis (Figs. 22,23). The decreased prevalence of angular cheilitis over the
study may be a result of rapid and effective treatment of infections by hospital
staff and also improved patient nutrition.
Lip ulceration was present in 13% of patients on admission decreasing to 3%
at the three months assessment (Fig 40,41).
Various studies have quoted the prevalence of oral ulceration in HIV infected
individuals as between 2 - 4% (264). The design of the patient assessment
form did not allow for a detailed clinical description of peri-oral and oral
ulceration. Biopsy of the lesions was not possible hence more detailed
comment is not available (Fig 42,44,45). The presence of atypical ulceration
observed on the tongue may also be due to TB (226,227) (Fig 46).
Severe haemorrhagic crusting of the lower lip was observed in 14% of
patients, both on admission and at three months (Fig 43).
A range to the clinical appearance of linear gingival erythema was noted in the
study population (Fig 20,21). Recent reports have suggested Candida sp. may
play role in the aetiology and pathogenesis of LGE (37,268). Candida
dubliniensis has been identified in the gingival crevice of paediatric patients
with LGE (37). An increased prevalence of Candida dubliniensis in HIV
positive patients with poor oral hygiene and the co-aggregation of C.
dubliniensis with Fusobacterium nucleatum have been reported (29,35,38).
To date there has been no specific research into the oral manifestations of
patients co-infected with HIVand TB. The administration of antibiotics causes
a change in the oral microflora leading to greater numbers of Candida sp., and
an increased risk of Candida infection. (135,137,274-5). Medical researchers
investigating TB in HIV / TB co-infected patients have reported a high
incidence of oral and pharyngeal candidosis in these patients (244,276).
A change in the prevalence of clinical type of oral candidosis was noted in the
study group. There was a shift from the pseudomembranous type of oral
candidosis (prevalent on admission) to the erythematous type of oral
candidosis (prevalent at three months). This shift was common to all the
..I'
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surfaces of the oral mucosa (Fig 38 & Fig 39). The parameters of this
investigation preclude any further comment as to whether the change
observed in this study population was a feature of HIV infection I AIDS alone,
or whether other factors such as medication, malnutrition and
immunosuppression due to TB, also played a role.
Atrophy of the dorsum of the tongue is commonly seen in patients undergoing
prolonged antibiotic therapy (148). The oral microflora of these patients is
altered, allowing resistant organisms such as C. albicans to flourish. On
admission 86% of patients had varying degrees of atrophy associated with the
dorsal surface of the tongue (Figs. 30&39). In addition to atrophy, 54% of
patients on admission had clinical evidence of oral candidasis. At the final
three months examination a high proportion of patients (83%) still showed
atrophic changes to the dorsum of the tongue. A smaller percentage (48%) of
patients had clinical evidence of oral candidasis.
Atrophy of the tongue has a multi-factorial aetiology (148). It is most likely a
combination of ongoing vitamin deficiency I malabsorption, Candida infection
and antibiotic related mucosal changes. It has not been reported in the
medical literature as a significant clinical finding in HIV I AIDS patients and
may be related to the specific circumstances of the study population.
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Figure 38. An example of oral candidosis associated with the
lower lip
Figure 39. Atrophic form of oral candidosis associated with the dorsum and
dorso-Iateral aspect of the tongue
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Figure 40 Lip ulceration Figure 41. Lip ulceration
Figure 42. Oral ulceration I white patch
Fig 43. Acute generalised oral candidosis and haemorrhagic crusting of the
lower lip.
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Figure 44. Large irregular ulcer Figure 45. The same patient with
a large ulcer displaying
an inflammatory halo.
Figure 46. Ulcerative lesions associated with the dorsal surface
of the tongue.
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6.2 Candidasp. identification
This study used an oral rinse sampllnq technique to assess Candida sp.
carriage in the oral cavity. StuJies investigating yeasts have employed a
variety of methods (31,33,35,277). The oral rinse method to quantify yeast
carriage was found to be simple to perform and as sensitive as other
techniques (49).
CHROMagar is a commercial chromogenic culture medium that facilitates the
isolation and presumptive identification of Candida sp. (Fig 1.)(32,75,278,). A
study found that C.albicans, C.tropicalis, and C.krusei have a distinctive
appearance on primary CHROMagar isolation (Fig 2,3,4). These three
species can be recognised quickly and accurately by trained operators (75).
This study confirmed that C.tropicalis and C.krusei could be identified from the
primary isolation on CHROMagar with a high degree of accuracy.
Recent studies indicate that CHROMagar alone should not be used for
definitive Candida sp. identification. Although the author could not corroborate
the findings, other studies have reported that C.albicans can produce two
chromogenic forms; light green colonies with paler edges and smaller dark
blue/green colonies (Fig 4,5). The latter description has also been ascribed to
C.dubliniensis (Fig 5.).
This study found that a range of additional investigations including
carbohydrate fermentation and assimilation, growth at various temperatures,
Beta-D-glucosidase activity, chlamydospore and germ tube formation allowed
for accurate species differentiation (73,261,262,277,279,280-2)
Three isolates that appeared as homogenous white colonies at initial
CHROMagar isolation, tested germ tube positive. Subsequently sugar
assimilation profiles using both the disc diffusion method and the API ID 32C
system identified the species as C.tropicalis (Fig 31.). This species of Candida
has strains that are positive for the germ tube test. It is also possible that the
sample colony contained C.albicans thus accounting for the positive germ
tube test result.
Although it has been sufficient to use bio-chemical tests to identify Candida
sp. in the past, current medical knowledge demands research differentiates to
strain level.
6.3 Candida species
C.albicans is the most common cause of opportunistic fungal disease in
humans (283). C.albicans was the most frequently isolated species of
Candida both on admission and at three months (Fig 34). The prevalence of
C.tropicalis, C.glabrata and C.parapsilosis found in this study population all
lay within the isolation rates quoted in the research literature (284-5). There
was no significant change in the prevalence of C.albicans observed over the
study period (Fig 34). C.tropicalis showed a significant decrease over the
study period. C. parapsilosis showed a small increase, while other non-
Candida albicans species showed little variation (Fig 34). Antibiotic use has
been documented as a predisposing factor for C. parapsilosis infections
(53,286).
Researchers studying candidoses have reported an epidemiological shift
towards infections caused by non-C.albicans sp. (284). One hypothesis that
may account for this shift is that these latter species, unlike C.albicans, can
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persist in the oral cavity following antifungal treatment (287). C.glabrata and
C.krusei are less susceptible to antifungals such as fluconazole.
C.dubliniensis, while susceptible to the common antifungals, has a reduced
susceptibility to fluconazole in AIDS patients who have previously been
treated with the drug. Although various authors have speculated as to the
underlying causes of this shift, no firm evidence has yet been advanced.
The traditionally held view is that the hyphal form of the Candida sp. is
associated with the disease state and blastospheres are present in the
commensal/non-infective state. Research has indicated that the hyphal form
can occur at healthy sites within the oral cavity and the yeast form, for
instance C. glabrata, can cause infection (19,284-5).
Candidasis as a side effect of medical treatment has been increasing over the
last two decades. The use of antibiotics is one of the major factors that
increase the risk of developing candldosls. The nosocomial environment is an
important factor in the increased incidence of candidasis. One study indicated
an eight-fold increase in nosocomial fungemia, the main source of which were
Candida sp. (9). Researchers from the USA noted that the number of
nosocomial bloodstream infections due to Candida species is increasing, with
non-C.albicans species, in particular C.glabrata, an important nosocomial
pathogen (288 -92). Hospital studies found that 17 to 58% of hospitalised
patients and health personnel carry Candida sp. on their hands, with
C.parapsilosis the most common pathogen isolated (286,293-95). One study
found nursing personnel were a potential infectious source of Candida sp.
(296). Analysis of DNA shows that Candida sp. can be transmitted to patients
in the nosocomial environment (297). There are a number of vehicles for
transmission including hospital personnel, visiting family of hospitalised
patients and contaminated food (298-9). One study found that the longer the
period of hospitalisation and immuno-suppression, the greater the risk of
developing a candidal infection (300).
For a number of reasons Brooklyn Chest Hospital has a large turnover of both
in- and out-patients undergoing treatment for TB. Medical and nursing staff
moves between paediatric and the adult wards throughout the working day.
This study did not investigate the possibility of cross-infection between
patients and also between patients and staff. It is possible that cross infection
may have had a dramatic effect on the oral Candida sp. profile of the study
population, particularly in terms of anti-fungal agent resistant species. This
nosocomial transmission is of crucial importance to neonates and young
infants in the BCH paediatric wards as studies have reported this group to be
at particular risk from candidal infections (292,301-04)
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6.4 C. dubliniensis
This is the first study to identify C. dubliniensis in the South African HIV/AIDS
population. This study concurs with the findings of other researchers, that is
the differential diagnosis between C. albicans and C. dubliniensis using the
colour and morphological characteristics of colonies on CHROMagar is
unreliable (31). Several studies have reported that C.dubliniensis more often
produced colonies of dark green appearance on primary isolation on
CHROMagar (32,278)(Fig 5). In this study some dark green colonies initially
labelled as C. dubliniensis after isolation on CHROMagar demonstrated good
growth at 45°C and demonstrated a positive result for beta-D-glycosidase
activity. These results indicated that C.albicans could also form dark green
colonies on CHROMAgar. This study did not established whether the
converse was also true. Other studies have reported that the light green
colonies can also correspond to C. dubliniensis (31). It has been reported that
the colour of the Candida colonies on CHROMagar deepens with time (75).
Due to this phenomenon the manufacturer recommends that optimum time for
identification should be after 48 h. This study found that if the CHROMagar
plates were kept for three weeks in a refrigerator at 4°C, the light green
colonies identified as C. albicans (using the tests outlined in the methods)
deepened to a dark green, whilst the darker green colonies identified as C.
dubliniensis deepened to an inky black colour (Fig 25,27). This adds another
useful marker for C. dubliniensis.
This study used a variety of tests to positively identify C. dubliniensis
(30,32,73,78,136,262,277). Previous studies have indicated that C.
dubliniensis differs phenotypically from C. albicans by its production of
abundant chlamydospores and its failure to grow at 45 °c (73,26~. Results
from this study show that poor growth or an inability to grow at 45 C can be
used as a marker for C. dubliniensis (262)(Fig 13).
One study found that chlamydospore formation on Staib agar was a species-
specific characteristic for C.dubliniensis (73). This study could find no
consistent evidence of hyper production of chlamydospores.
For the beta-D-glycosidase activity test only those isolates that showed no
evidence of fluorescence were reported as negative (27,277). Only one isolate
from the study population demonstrated clear non-fluorescence. The author
noted that there was a marked variation in the intensity of fluorescence
amongst those isolates demonstrating beta-D-glycosidase activity. One
possible explanation for the variation in fluorescence is the presence of both
C.albicans and C.dubliniensis in the sample examined.
Substrate assimilation profile using the ID32C and other yeast identification
systems did not consistently identify any common pattern in those isolates
identified as C. dubliniensis (281). A report outlining a new product VITEK 2
10-YST suggests that this system will be able to provide an accurate specific
assimilation profile for the species (279). Molecular and gas-liquid
chromatography technology can also permit accurate, single procedure
identification of C.dubliniensis using a species-specific molecular beacon (76-
8,305).
C. dubliniensis is reported to be more adherent to human buccal mucosa
epithelial cells than C.albicans isolates, which suggests that this species may
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be particularly adapted to colonisation of the oral cavity (36). C.dubliniensis
may operate as a lone pathogen or in symbiosis with other oral
microorganisms (38). These facts are particularly significant in the light of the
role that other non - C. albicans species play in diarrhoea of hospitalised
paediatric patients and the attendant risk of the nosocomial spread
(6,9,10,11,12).
This preliminary data suggests that the prevalence of C. dubliniesis in
HIV/AIDS patients in South Africa (3%) is lower than in other studies. An Irish
study found that C. dubliniensis was recovered from 27% of the oral cavities
of HIV-infected individuals and 32% of AIDS patients suffering from oral
candidosis (27). This variation may be due to several factors such as inter-
study variation in performing the identification tests, geographic variance in
the oral profile of Candida species and the availability of anti-fungal
medication in South Africa. Further research in HIV sero-positive and HIV
sero-negative individuals is required to establish a baseline for C. dubliniensis
in the South African population.
6.5 Candida sp. load
A 50% reduction in the Candida load was observed over the three months
study period (Fig 10). The female study population demonstrated a greater
reduction in Candida load than their male counterparts (Fig 11).
A complex series of factors may account for these changes;
• A regular, balanced and supervised diet,
• Vitamin and iron supplementation where required,
• Use of prophylactic nystatin
• Treatment of severe recurrent Candida infections with fluconazole
• Use of anti-microbial mouthwashes to control and treat secondary oral
infections
• The prohibition of smoking and drinking in the hospital,
• The employment of the DOT system (Directly Observed Treatment) for
the in-patient Tuberculosis therapy,
• Concomitant infections treated and sensitivities obtained where
required,
• Encouragement with personal and dental hygiene measures.
The instruments used in this study do not allow for a more detailed analysis in
the variation of Candida load between the male and female populations of the
study.
6.6 Anti fungal regimes at the Brooklyn Chest Hospital
The scale and variety of patient management at the BCH necessitate that all
medications, including oral topical anti-fungal preparations, be administered
before breakfast. Researchers found that many of the anti-mycotics available
for the treatment of oral candidosis are diluted by saliva and by the cleansing
action of the oral musculature. This reduced the availability of the antifungal
agents below that of effective therapeutic concentration. These studies
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indicate that sub-therapeutic levels of topical antifungals may modulate
candidal colonisation of the oral mucosa (306-08).
95% of the study population were placed on long term prophylactic Nystatin
anti-fungal medication for varying periods of their in-patient stay. Medical
residents are rotated from Tygerberg Hospital to the Brooklyn Chest Hospital
on a three monthly basis. This ractor could account for the wide variation in
provision of Nystatin medication. Brooklyn Chest Hospital does not have a
protocol for the provision of anti-fungal agents for their HIV positive patients.
There was little change observed in the prevalence of C.albicans over the
study period (Fig 34). Other non-Candida albicans species showed a
decrease in prevalence (Fig 34). This might be accounted for by the fact that
Nystatin is more affective at suppressing the adhesion of non-C.albicans
species than C.albicans (306,309-10).
Fluconazole was prescribed for severe cases of oral candidosis. Prior
approval had to be obtained from the Hospital Administrator for each 10-day
course of fluconazole. Again variations in prescription protocols were
observed among patients. A total of 8 patients received one or more 10-day
courses of fluconazole for treatment of oral candidosis. One patient received
fluconazole for the duration of her inpatient stay.
6.7 Resistance to anti fung"JIagents in the study population
Antifungal resistance can be divided into two categories; clinical resistance
and in vitro resistance.
Clinical resistance signifies a lack of clinical response to the antifungal agent
used which may denote low levels of the agent in the serum, or in I around the
tissues. Two of the most important reasons for low levels are, non-compliance
and incorrect application. In AIDS patients antifungal agents even a very high
doses may not completely eradicate the fungi from the host.
In vitro resistance can be subdivided into primary and secondary resistance.
Primary resistance is where the organism has an innate or intrinsic resistance
to the agent, for example C.krusei to fluconazole (57). Secondary or acquired
resistance is described when the isolate producing the infection becomes
resistant to the antifungal agent. This form of resistance was rare in the past,
however it is now the most frequently reported form in AIDS patients who
suffer recurrent azole resistant oropharyngeal or oesophageal candidosis
(232-35). Prior exposure to antifungal medication may affect subsequent
responsiveness to antifungal therapy (57,232-36,311-14). Studies have
detailed the development of fluconazole resistance to clinical isolates of
Candida sp. not previously exposed to the antifungal medication (210,315).
The author was not able to discover any records of previous antifungal
medication exposure for the study population prior to admission to the BCH. It
is possible that multiple genotypes are present in the oral cavity. Primary
identification of Candida sp. was performed using the phenotypical
characteristics of the isolates on CHROMAgar. Subsequent selection and
sub-culturing of a single colony may have resulted in the elimination of certain
genotypes and so may not have allowed for consistent selection of genotypes
for antifungal sensitivity testing. Hence the author cannot comment on any
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relationship between antifungal regimes and decreased anti-fungal agent
susceptibility.
None of the study population exhibited resistance to Nystatin. However
resistance to Nystatin has been reported in the literature (311). All but one
isolate had levels of Amphotericin B susceptibility below 6 ug/ml (Table 5).
Susceptibility to Fluconazole decreased by 10% over the three months study
(Table 4). There was an increase of 1% in the number of patients who showed
fluconazole susceptibility of greater than 128 ug/ml. There are a number of
factors that may have influenced these results.
Research into the treatment and management of non-C.albicans oral
candidasis indicate that important susceptibility patterns are emerging for
these yeasts (2). Amphotericin B is extremely active against most Candida sp.
and general resistance is rare. However Amphotericin B may not be the agent
of choice for infections caused by C.parapsilosis, C.glabrata and C.kefyr
(Table 5). An oral rinse taken on admission from one male patient gave an
isolate of C.glabrata resistant to Amphotericin B (Table 5)(316). Although
C.glabrata isolates give higher minimum inhibitory concentration values for
Amphotericin B, it is generally sensitive to the antifungal agent (316). The
antifungal agent flucytosine is reported to have greater action against
C.glabrata (19).
Both isolates of C.krusei identified in this study were resistant to fluconazole.
This Candida sp. is innately resistant to fluconazole (Table 4)(19,57). All
C.glabrata species isolated in this study demonstrated a low sensitivity to
fluconazole (19, 236).
C.dubliniensis was isolated in one patient both on admission and at three
months. The isolate of C.dubliniensis at three months displayed an MIG
greater than 256 ug/ml indicating fluconazole resistance. This patient received
one 10-day course of fluconazole during the study period. Although this C.
dubliniensis isolate displayed a lack of sensitivity to fluconazole, it remained
susceptible to Amphotericin B (Table 4)(40). Studies have reported that the
development of fluconazole resistance by C.dubliniensis may depend on the
dosage of drug administered, the duration of therapy, or the immune status of
the patient. These aspects of fluconazole resistance have also been
documented for C.albicans (317). Investigations in vivo suggest that Candida
populations including that of C.dubliniensis may have the ability to respond in
a dynamic fashion to antifungal therapy and may involve changes in gene
expression. Studies have suggested that C.dubliniensis, unlike C.albicans
appears to possess the ability to rapidly develop stable resistance to
fluconazole following direct exposure to the drug in vitro. An Irish study has
reported that C. dubliniensis encodes multi drug transporters which facilitate
efflux of fluconazole from the cell via specific multidrug transporters
(MDR1)(41).
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6.8 Garlic
Studies have suggested that the herb garlic has antibacterial and anti fungal
properties (217 - 225). Allicin and Ajóene are constituents of the herb garlic
(226). Unpublished data from a study using Ajoene distilled from fresh garlic
suggests that it possesses potent anti-fungal properties. This study made use
of a synthetic Ajoene synthesised by Professor Hunter of the University of
Cape Town. This preparation showed poor anti-fungal properties. A possible
explanation may be that samples of naturally distilled Ajoene contain
impurities that are essential for potentiating its anti-fungal properties. The
Allicin used in the study was distilled from the fresh herb source and
demonstrated significant anti-funqal properties. It showed weak or no anti-
fungal action against the resistant isolates of C.krusei and C.glabrata. This
adds strength to the proposition that fresh garlic possesses significant anti-
fungal properties. Unfortunately the unpleasant smell and long after taste of
garlic prevent its widespread use as a treatment modality.
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Chapter 7
Conclusions
A large percentage of patients presented with oral lesions, both on admission
to the BCH and at the end of the study period.
Oral candidasis was the most commonly diagnosed oral lesion in the study
population. The- author could find no literature source that specifically
investigated the oral lesions of HIVITB co-infected patients. However oral
candidasis is the most commonly observed oral lesion in HIV/AIDS patients.
The clinical type of oral candidasis found in the study population changed,
from the pseudomembranous type prevalent on admission, to the
erythematous type prevalent at three months.
The erythematous type of oral candidasis is associated with AIDS patients.
C. albicans was the most commonly isolated species of Candida in the study
population, both on admission and at three months. There was no evidence of
a significant change in the prevalence of non-Candida albicans species over
the study period
C.dubliniensis was identified for the first time in South Africa.
Fewer species of Candida were isolated from the oral rinses at three months.
There was a significant reduction in Candida load, as defined by colony
forming units per millilitre, over the study period. This reduction was observed
in both the male and female study population.
Resistance to fluconazole increased over the study period. One isolate
obtained at three months and identified as C.glabrata was resistant to
Amphotericin B. None of the Candida species isolated during the study
exhibited resistance to Nystatin.
Allicin, a component of natural garlic, appeared to possess good antifungal
properties. The synthetic ajoene demonstrated poor antifungal properties.
Factors present in the natural garlic may play an important role in potentiating
the antifungal properties of these compounds.
In conclusion, there was a significant change in the oral carriage of Candida
species, both in terms of Candida species identified and Candida sp. load.
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Chapter 9
Appendices
Patients oral examination for
DATE: / /
Patients Details
Patients Name:
Address:
Hospital Number: .
Date of Birth: / /
Male / Female: M F
Social History:
Ethnic Origin: .
Occupation: .
Marital Status .' .
Children .
Alcohol:
Current..... Past. ..... Never. ..... How long stopped yrs mths
Current/Past: Age started Yrs Age stopped yrs Average units/week .
Drinker
Tobacco:
Current... Past . Never . How long stopped yrs mths
Current/Past Cigarettes... . Pipe... Other .
Numbers smoked/day... Age started Yrs Age stopped yrs
Intravenous drug use
History/signs of IVDU: : .
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General Medical History:
Relevant Medical History:
Current medication I Drug treatrnenc
Date of commencement .
Relevant medical history (cont'd)
When diagnosed HIV positive: .
Where diagnosed HIV positive , .
CD4 count (if known): ..
Viral load (if known): .
When diagnosed TB positive: .
Where diagnosed TB positive : '" .
Details of previous episodes of TB and
outcome: ..
Extra oral examination
Clinical Details
Swelling YIN
Sinus YIN
Lymphadenopathy YIN
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Lips Normal/Abnormal
Facial tissues Normal/Abnormal
Muscles of Mastication Normal/Abnormal
Intra oral examination
Lips and vermillion border &
Labial mucosa
Normal/Abnormal
Commisure of mouth Right Normal/Abnormal
Left Normal/Abnormal
Buccal mucosa Right Normal/Abnormal
Left Normal/Abnormal
Mucobuccal fold Right Normal/Abnormal
Left Normal/Abnormal
Tongue Ventrum Normal/Abnormal
Lateral Normal/Abnormal
Dorsum Normal/Abnormal
Floor of mouth Anterior Normal/Abnormal
Posterior Normal/Abnormal
Hard Palate Normal/Abnormal
Soft Palate Normal/Abnormal
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Pillar of Fauces Right Normal I Abnormal
Left Normal I Abnormal
Gingival tissues Free Normal I Abnormal
Attached Normal I Abnormal
CPITN Score
Additional clinical findings '" .
Candidal infection
Clinical Details
Present
Lesion - single I multiple I wipes off
Site
Surface Appearance
Size
Consistency
Other associated lesions
Pseudomembranous
Erythematous
YIN
YIN
YIN
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If palate involved
Pin point hyperaemia YIN
Diffuse hyperaemia YIN
Granular YIN
Hyperplastic YIN
Plaque like
Nodular type
Median Rhomboid glossitis YIN
YINAcute I chronic atrophic
Candida associated Angular chelitis YIN
Extra information:
Patient info sheet given
History and examination taken by: .
Name .
Signature: .
Date: .
Location: .
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